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Acute kidney injury (AKI) is a rapid loss of normal kidney function and is 
accompanied by a dysregulation of cellular and mitochondrial metabolism, which can 
be observed before organ dysfunction. A hallmark of AKI is the early and persistent 
disruption of mitochondrial homeostasis. Mitochondrial biogenesis (MB), the process 
by which new mitochondria are generated, has been shown to prevent injury and 
increase the rate of recovery of ischemia-reperfusion injury (IRI)-induced renal 
dysfunction. However, the molecular mechanisms mediating MB and dysfunction 
following IRI remain unclear.  
We elucidated that extracellular signal-regulated kinase 1/2 (ERK1/2) regulates 
two key mitochondrial and cellular metabolism pathways following AKI. The first is 
the rapid downregulation of MB through decreased peroxisome proliferator-activated 
receptor gamma coactivator-1α (PGC-1α) expression, the master regulator of MB. The 
second is nicotinamide adenine dinucleotide (NAD) loss after IRI, particularly the 
oxidized form, NAD+. 
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 Trametinib, an FDA approved drug, prevents ERK1/2 activation by inhibiting 
mitogen-activated protein kinase kinase 1/2 (MEK1/2). ERK1/2 inhibition prior to IRI 
prevents the downregulation of PGC-1α gene expression. In addition, trametinib 
prevented PGC-1α acetylation, which deactivates PGC-1α, after IRI. This was verified 
by determining that trametinib inhibited the loss of downstream PGC-1α and MB targets 
after IRI, including both nuclear- and mitochondrial-encoded genes.  
NAD+ is a vital coenzyme in cellular metabolism, redox signaling, and 
contributes to overall cellular health. NAD+ is depleted during injury, and restoration or 
prevention of this depletion averts worsening injury and often promotes recovery. 
Inhibition of ERK1/2 activation attenuated NAD+ loss and was mediated through 
increased nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme 
of the NAD+ biosynthetic salvage pathway. Inhibition of renal ERK1/2 activation 
decreased miR34a, a known regulator of NAMPT, and led to an increase in NAMPT 
protein.  
In conclusion, inhibiting ERK1/2 activation restored PGC-1α protein levels, 
attenuated the loss of downstream MB targets, increased NAMPT protein, and restored 
NAD+ after IRI. These cellular alterations ultimately led to restored kidney function 
following IRI-induced AKI. These studies may help support the identification of 
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RENAL ANATOMY AND PHYSIOLOGY 
Overview 
 Normally there are two kidneys working simultaneously in the human body 
filtering blood to maintain fluid homeostasis by removing waste products and extra 
fluid. The kidney maintains the proper balance of fluid volume, electrolytes (sodium, 
potassium), minerals (calcium, phosphorous), and blood pH. By maintaining proper 
fluid homeostasis all the other organs are able to function properly. In addition to fluid 
homeostasis, the kidneys also serve a critical role in eliminating harmful toxins, 
xenobiotics, and waste products (ex. ammonia and urea) that can build up in the 
circulatory system, and cause harmful side effects. Two other major contributions to a 
healthy functioning body are the control of blood pressure and the production of red 
blood cells. Blood pressure is controlled through both fluid homeostasis and through 
the secretion of the hormone renin and subsequent renin-angiotensin-aldosterone 
signaling pathways. The kidneys contribute to the creation of new red blood cells by 
releasing the hormone erythropoietin, which signals the bone marrow to produce more 
red blood cells, often as a way to increase oxygen supply to the rest of the body. The 
kidney anatomy can typically be divided into three regions (working from outermost 
to inner): the renal cortex, the renal medulla (consisting of the outer and inner 






 The kidney consists of around a million nephrons, which are considered the 
basic functional unit of the kidney. The nephrons filter, excrete, and reabsorb solutes 
and fluid to help maintain fluid and electrolyte balance through complex pressure and 
gradient pathways. Blood enters the nephron via the renal artery and into the section of 
the nephron called the glomerulus. The glomerulus is the first step in the filtration 
process and the filtrate then flows into the renal tubule. The renal tubule is comprised 
of the proximal tubule, ascending and descending limbs of the loop of Henle, the distal 














 Blood from the renal artery enters the glomerulus via the afferent arterioles and 
is filtered in the glomerular capillary bed. Blood that passes through the glomerulus 
without being filtered exits via the efferent arteriole and consists of larger molecules, 
such as various blood cells and higher molecular weight proteins. The efferent blood 
continues flowing to supply the renal cortex and the renal medulla and papilla, as well 
as allow for the return of water and solutes the tubule filters and reabsorbs. The renal 
cortex filters around 90% of the renal blood flow. This disparity in blood flow within 
the kidney is due to the cortex consisting of mainly proximal tubules which rely 
heavily on oxidative phosphorylation for energy production, which requires more 
oxygen availability and therefore more blood flow. The renal medulla and papilla 
utilize mainly glycolysis for energy production and requires less oxygen than the 
proximal tubules. The small capillaries eventually return to the renal venules to form 
segmental renal veins. The renal vein then takes blood away from the kidney that has 






The purpose of the glomerulus is to be the beginning step of the blood 
filtration process. The thin walls allow water and waste products to pass through the 
glomerulus and into the tubule where further filtration and concentration can occur. 
Glomerular filtration can be affected by changes in blood volume, blood pressure, and 
vascular tone to the afferent and efferent arterioles. The afferent arteriole blood flows 
into the glomerulus and into an area called Bowman’s capsule. Blood is filtered 
through various layers of cells and membranes composed of capillary endothelium, 
glomerular basement membrane, and podocytes. Podocytes are a specific cell type that 
are found on the outside of capillaries inside the Bowman’s capsule. Substances found 
in the blood generally are filtered depending on their size and charge. Smaller 
molecules can pass through and into the renal tubules, whereas proteins greater than 
~60 kDa continue into the efferent arteriole. Smaller proteins that are highly anionic 
are potentially limited in their filtration, most likely due to the glomerular basement 
membrane also being anionic, causing a repulsion effect. The rate at which blood is 
filtered in the glomerulus and the fluid passes into the tubule is termed the glomerular 
filtration rate or GFR, and is used as a renal functional diagnostic test in hospitals and 
laboratory settings. A person with no kidney disease will typically have a GFR of 
greater than 60 mL/min, and a GFR under 60 mL/min is diagnosed with some form of 




The Proximal Tubule 
 The glomerular filtrate passes through the Bowman’s space and into the 
proximal tubule, where the filtrate is further filtered. The proximal tubule further 
reabsorbs both fluid and electrolytes, including a majority of the water that passes 
through the glomerulus. Electrolytes and ions are reabsorbed here by way of ion 
transporters, including sodium chloride, potassium, calcium, phosphate, and 
bicarbonate, where they enter back into the systemic blood supply. Glucose, 
carbohydrates, and various amino acids are also reabsorbed here through active and 
facilitated diffusion. As mentioned earlier, the proximal tubules have a high-energy 
demand and thus utilize oxidative phosphorylation for ATP production. The 
abundance of the various transporters and the activity of reabsorption places a high-
energy burden (need for ATP) on the proximal tubules and oxygen demand; which 
highlights why the renal cortex receives 90% of the blood supply. The proximal tubule 
can be further divided into 3 sections: the S1, S2, and S3 segments. The S1 segment is 
where around 90% of the glucose is reabsorbed, and most of the bicarbonate, amino 
acids, and other carbohydrates. The S2 and S3 segment reabsorb the remaining 
glucose and has organic anion transporters involved in the secretion of various 
exogenous compounds, including antibiotics, NSAIDs, methotrexate, etc. The fluid 
passes into the Loop of Henle and ultimately into the bladder as urine. 




Loop of Henle – Distal Tubule – Collecting Duct 
 The Loop of Henle is a U-shaped section of the nephron, and consists of the 
thin descending and ascending limbs and a thick ascending limb. In the descending 
limb additional water is reabsorbed, further concentrating the filtrate. As the fluid 
enters the ascending limb, sodium chloride is further reabsorbed by diffusion and as 
the fluid reaches higher segments of the ascending limb, sodium chloride and 
potassium can be actively transported out of the filtrate, if necessary. In a person with 
high sodium intake, these transporters will not be utilized to the extent of a person 
with very low sodium intake. The remaining sodium chloride is expelled in the urine. 
The distal convoluted tubule receives the fluid from the ascending limb and is a major 
area of pH regulation. The distal tubule maintains proper pH by absorbing and/or 
secreting bicarbonate and protons (H+) into the filtrate. Sodium and potassium can be 
further influenced in the distal tubule and is where the thiazide diuretics mechanism of 
action is located. Thiazide diuretics inhibit the sodium chloride reabsorption in the 
distal tubule by inhibiting the sodium chloride symporter. The fluid passing through 
the distal tubule flows into the collecting duct that acts as a connecting region from the 
tubules to the minor calyx or renal pelvis. The collecting duct is the final area of 
electrolyte and water reabsorption. Normally the collecting duct reabsorbs around 5% 
of the sodium and 5% water, however during times of dehydration, and in the presence 
of antidiuretic hormones, the collecting duct may reabsorb much more water to 
prevent bodily harm due to dehydration. Both aldosterone and vasopressin have 
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effects on the collecting duct’s reabsorption and filtration system. Aldosterone 
increases sodium and water reabsorption and increases potassium excretion. 
Vasopressin increases the amount of water reabsorbed without altering solute 
reabsorption by increasing aquaporin channels, ultimately creating urine that is more 
concentrated. Fluid remaining in the collecting duct will enter various regions of the 
kidney in succession: the minor calyx, major calyx, renal pelvis, ureter, and bladder. 
Once in the bladder, the urine can be expelled. A diagram is provided below that 
depicts the kidney gross anatomy and inner nephron together with the renal 








ACUTE KIDNEY INJURY 
Definition and Clinical Classification 
 Acute kidney injury (AKI) is defined as the rapid and abrupt loss of normal 
renal function (usually within less than 7 days). Decreased urine output, electrolyte 
and mineral imbalance, improper fluid balance, and an increase of waste products in 
the serum are all potential symptoms of AKI. Two of the most well-known waste 
products that become elevated are creatinine and urea. An older term for an abrupt loss 
of kidney function was acute renal failure (ARF). This term has been phased out in 
lieu of AKI, to more properly demonstrate the reality that less severe kidney injury 
(i.e. not reaching kidney failure status) can still have a detrimental impact on the 
patient’s renal function and overall health. Clinically, a patient will be categorized as 
having AKI by their estimated glomerular filtration rate (GFR), which requires their 
serum creatinine (SCr) and urine output. The American Journal of Kidney Diseases 
and the National Kidney Foundation released 2018 AKI guidelines, titled, 
“Management of Acute Kidney Injury: Core Curriculum 2018.”  These guidelines 
utilized three distinct classification systems (Figure 1.4): 1) Kidney Disease: 
Improving Global Outcomes (KDIGO), 2) Acute Kidney Injury Network (AKIN), 3) 
Risk, Injury, Failure, Loss, and End-stage renal disease (RIFLE) [1].  
The overall comparisons of the three different classifications can be found below in 
Figure 1.4, taken from the American Journal of Kidney Diseases and the National 
Kidney Foundation 2018 AKI guidelines (Figure 1.4). The RIFLE classification is the 
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lone system that contains five different categories versus three for the other 
classification systems. RIFLE associates varying degrees of kidney dysfunction to the 
five criteria levels:  
 
1) Risk- defined as a ≥ 1.5-fold increase in SCr within 7 days and sustained for ≥ 24 hr 
in conjunction with urine output < 0.5 mL/kg/h for 6-12 hr  
2) Injury- is a ≥ 2-fold increase in SCr and urine output < 0.5 mL/kg/h for ≥ 12 hr 3) 
Failure- is a SCr ≥ 3.0 mg/dL OR SCr increase to ≥ 4.0 mg/dL with an increase to 0.5 
mg/dL OR initiation of renal replacement therapy (RRT), in combination with < 0.3 
mL/kg/h for ≥ 24 hr or anuria for ≥ 12 hr  
4) Loss- is the complete loss of kidney function for > 4 weeks  
5) ESKD- is end-stage kidney disease defined as a sustained absence in renal function 
for > 3 months. 
 
RIFLE classification is one of the first systems to identify an increase in AKI severity 
as an independent determinant for increased mortality [9]. RIFLE is also one of the 
better systems for predicting patient outcomes, especially for patients in intensive care 
[9-13]. A few limitations are identified for the RIFLE classification system. One 
limitation is that a baseline serum creatinine is needed, and this number is routinely 
not known. Another limitation is the RIFLE system uses serum creatinine and urine 
output as its lone diagnostic markers, which gives no indication of where the injury or 
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dysfunction is originating from; in contrast with some of the newer renal injury 
biomarkers [9, 14-17]. Regardless, the various classification systems and 
standardization for renal dysfunction have allowed for a plethora of controlled studies 
to help determine causative correlations with morbidity and mortality, as well as being 







Figure 1.4: Comparison of Recent Consensus AKI Definitions. Table is 
from AJKD’s Core Curriculum 2018 update on Management of Acute 




Because AKI has been defined by various classification systems, and each could use 
different functional markers for the level of dysfunction, AKI incidence can vary 
significantly within reviews and renal studies. However, a thorough United States 
community-based study that followed nearly four million participants estimated the 
incidence of non-dialysis-requiring AKI to be approximately 384.1 per 100,000 
person-years and the incidence of dialysis-requiring AKI was 24.4 per 100,000 
person-years [18]. In the aforementioned study, males and the elderly experienced 
AKI at a higher rate than other populations [18]. Another study demonstrated that AKI 
incident rates could reach up to 65% in the critical hospitalized patients found in ICU 
settings [19]. Besides being an already common disorder in the hospital and ICU 
settings, studies suggest that AKI incidence may be increasing [20-22]. The reasons 
for this phenomenon range from better reporting, clearer guidelines and rules for 




Morbidity and Mortality Associated with AKI 
Mortality has been demonstrated to correlate with increased severity of AKI in 
hospitalized patient settings, such as cardiac surgery, major trauma, and critical illness 
[12, 23, 24]. In fact, approximately 24% of adults and 14% of children from mainly 
developed nations are associated with AKI mortality [2] (Figure 1.5). As one might 
expect as patients with higher level of care needed in a hospitalized setting, the 
mortality rate increases. Critically ill patients in the intensive care unit, requiring renal 
replacement therapy, have mortality rates around 55% [25, 26]. In a study following 
US military veterans, found that those with AKI had a long-term mortality rate two 
times larger compared to those vets without AKI [27]. As mentioned earlier under 
section AKI Epidemiology, reporting of AKI has increased, however, mortality from 
AKI is decreasing [10, 28].  Better diagnostics and supportive treatment care are the 
most likely reasons for this change in mortality [10, 28]. Morbidity associated with 
AKI is concomitant with patients who survive an initial acute injury, and these 
patients remain at high risk for poor outcomes and long-term mortality, as well as a 
significant financial burden [29]. Chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) are more likely to occur in patients who have had AKI in the past; in 
fact, AKI is an independent risk factor for CKD and ESRD leading to increased 
mortality and poorer outcomes [30-32]. An estimated 34 million people are 
hospitalized per year, with an estimated financial burden of around 10 billion dollars 




Figure 1.5: Pooled incidence rate of AKI by world zones. Studies used Kidney 
Disease Improving Global Outcomes (KDIGO) equivalent AKI definition. 
Adapted from [2] 
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Types of AKI 
AKI can be classified into three distinct categories based on the origin of the injury 
causing the AKI. The three categories are 1) prerenal, 2) renal or intrinsic, 3) 
postrenal. AKI incidents due to prerenal alterations in blood volume or a reduction in 
blood flow into the kidney are estimated at around 70% for community-acquired AKI 
and 40% for hospital-acquired AKI [33, 34]. Some prerenal AKI causes are cardiac 
surgery, septic shock, blood loss (ex. hemorrhaging), and vascular disease, which all 
ultimately decreases the amount of blood reaching the kidney causing ischemic 
conditions and injury and organ dysfunction. As mentioned previously, the renal 
epithelial cells of the proximal tubule mainly utilize oxidative phosphorylation to meet 
their energy demands of various transport processes [7]. With an ischemic injury, the 
oxygen levels plummet, significantly affecting the proximal tubules cells. Intrinsic 
renal injury is when the injury originates inside the kidney, usually within the nephron 
[35]. Medications, drugs, toxins, and ischemia are causes of intrinsic renal injury. 
Postrenal AKI is an injury originating in the urinary tract but not inside the kidney, 
commonly caused by an obstruction in the bladder or urethra [35]. This obstruction 




Causes of AKI 
AKI can be caused by various etiologies including septic shock, cardiac surgery or 
other major types of surgery, blood loss, vascular disease, urinary obstruction, and 
drug/toxicant exposure. In the critically ill and hospitalized patient, sepsis is the major 
cause of AKI and is responsible for nearly 50% of AKI cases [36]. Interestingly, the 
medications that patients receive in the hospital can cause AKI, such as 
aminoglycoside antibiotics, a plethora of chemotherapeutic agents, radiocontrast 
media, and certain pain medication (non-steroidal anti-inflammatory drugs-NSAIDs). 
Aminoglycosides, in particular, will accumulate in the proximal tubules cells of the 
kidney and cause phospholipid metabolism alterations leading to nephrotoxicity and 
decreased kidney function [37]. Aminoglycosides are very important life-saving 
antibiotics; however, their toxicity to the kidney can compound renal dysfunction, 
especially in ICU settings [38]. In a study following 61 patients in the ICU, 11.5% of 
patients developed aminoglycoside-associated nephrotoxicity [39]. One of the more 
well-known and studied chemotherapeutic agents, cisplatin, is associated with renal 
toxicity. Recent evidence suggests that a metabolite of cisplatin preferentially 
accumulates in the mitochondria and severely damages mitochondrial DNA [40, 41]. 
The renal proximal tubules have the highest density of mitochondria found in the 
kidney, which leads to cisplatin metabolite accumulation and mitochondrial DNA 
damage, and depletion of mitochondrial-encoded proteins [42]. Another common renal 
tubule agent is radiocontrast media [43]. Various imaging machines and techniques 
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need the patient to ingest or inject the media. This agent mainly affects patient 
population with preexisting renal impairment associated diseases; however, this 
population is also associated with needing radiocontrast media, causing increased AKI 
incidence [44, 45]. NSAIDs are a common over the counter pain medication that has 
been demonstrated to cause AKI, particularly in the elderly and people with poor renal 
function before starting on NSAIDs [46]. NSAIDs cause damage by reducing blood 
flow into the kidney by inhibiting prostaglandin production, and therefore affecting 
vasodilation and vasoconstriction of the renal vessels. NSAID use is also associated 
with acute interstitial nephritis (AIN), where inflammatory cells infiltrate the kidney 




Pathogenesis of Ischemia-Reperfusion Induced AKI 
As mentioned previously, ischemia-reperfusion (IR) is a common AKI etiology. 
Certain drugs and toxicants, major surgery  (cardiac surgery), as well as certain 
disease states including sepsis and vascular diseases are associated with reducing or 
stopping blood flow to the kidney causing ischemic damage [48-50]. The lack of 
oxygen and nutrients damages multiple cell types within the kidney and causes an 
inflammatory response.  The epithelial, endothelial, and inflammatory cells respond to 
this ischemic environment and contribute to the AKI, [51]. Below is a chart outlining 






Figure 1.6: Pathogenesis of ischemic AKI. The major pathways of GFR 
impairment in ischemic acute tubular injury are caused by ATP depletion in vascular 
and tubular cells. Numerous interactions exist between endothelial cells, WBCs, and 
epithelial cells in the pathophysiology of ischemic AKI. These interactions are 
bidirectional between the cells involved, and result in specific functional and 
structural alterations. Inflammatory mediators released from proximal tubular cells 
influence endothelial cell processes (e.g. increase vasoconstriction and expression 
of cell adhesion molecules) that in turn influence the interactions between WBCs 
and endothelial cells, leading to reduced microvascular flow and continued hypoxia 
within the local environment. Additional functional changes occur, such as a 
marked reduction in production of erythropoietin and 25-hydroxylation of vitamin 
D. Electrolyte accumulation can rapidly lead to requirement of renal replacement 
therapy. Metabolic acidosis as a consequence of AKI must also be carefully 
monitored. Abbreviations: AKI, acute kidney injury; FENa, fractional excretion of 
sodium; GFR, glomerular filtration rate; TGF-β, transforming growth factor β; 
WBC, white blood cell [24]. 
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The endothelial cells play a big role in renal damage due to IR injury. Endothelial cells 
are responsible for maintaining vascular permeability, proper blood flow, regulating 
vascular tone, as well as proper smooth muscle function [52, 53]. Even following IR-
injury, the kidney continues to receive poor blood flow due to the damaged 
endothelium. Vasoconstriction is left unchecked due to increased cytokine production 
and release from endothelial-adhered leukocytes, such as IL-1β, TNF-α, and ET-1, and 
decreased nitric oxide production following IR-injury [52, 54-56]. Other inflammatory 
cells are easily passed through the damaged vasculature including neutrophils, 
lymphocytes, and macrophages. These inflammatory cells will release inflammatory 
mediators that can cause vasoconstriction, further restricting proper blood flow [57, 
58]. Endothelial mitochondrial damage plays a role in endothelial-associated decreases 
in microvasculature density, and by protecting the mitochondria, the microvasculature 
becomes less injured [59, 60].  
 
Renal epithelial cells, particularly the renal proximal tubule epithelial cells (RPTC), 
are very sensitive to IR AKI. RPTC absorb and secrete many different substances and 
these processes consume high levels of ATP, and therefore RPTC rely on oxidative 
phosphorylation for their energy production. ATP depletion is a common occurrence 
after IR injury and causes dysfunctional cellular process, and ultimately cell death [61, 
62]. Loss of polarity, sodium-potassium ATPase transport activity, cytoskeletal 
alterations, and mitochondrial dysfunction are other key RPTC processes that become 
25 
 
dysfunctional after IR injury leading to poor renal outcomes [7, 63, 64]. Apoptotic and 
necrotic cell death are both observed following IR injury due to the aforementioned 
altered processes [61, 62]. Severely damaged RPTC will have disruptions in their 
adhesion complexes, making the RPTC unstable. If enough adhesion proteins are 
disrupted, the tubule epithelial cells will detach from the basolateral membrane and 
can form tubular casts in the tubular lumen, potentiating renal damage [7, 65]. New 
cells will migrate and take up the space where the previous RPTC was and replace the 
old dead epithelial cell. The exact source of these cells range from bone marrow 
stromal cells, renal specific stem cells, and surviving renal epithelial cells 
dedifferentiating [66-68]. Most recent evidence suggests that RPTC that become 
damaged but do not undergo necrosis or initiate apoptosis, may actually 
dedifferentiate, and migrate along the basement membrane and redifferentiate to 
restore lost epithelial cells [65, 69]. The differentiated epithelial cells will undergo 
gene and protein expression changes to express stem cell-related markers that help in 
the repair processes, and become a renal-specific cell that resembles a typical stem 
cell, [70-72]. Below is a diagram of normal repair in ischemic AKI, and two different 





Figure 1.7: Normal Repair in Ischemic AKI. Following ischemic renal injury, 
renal epithelial cells lose their polarity and brush border with proteins translocated 
from the basolateral membrane to the apical membrane. In the case of severe 
ischemia, cell death occurs via necrosis and/or apoptosis. Necrotic debris and 
detached viable cells are released into the lumen, potentiating renal dysfunction. 
Viable cells undergo division to replace lost cells, and subsequent differentiation 






As mentioned previously, mitochondria play a substantial role in providing the ATP 
requirements for the various transport processes required to filter blood constantly in 
the renal proximal tubules. As the main organelle in the RPTC for energy production, 
any dysfunction to the mitochondria will have detrimental effects on the RPTC and 
impair the transport processes, leading to improper absorption and secretion [73-75]. 
Studies have demonstrated that mitochondria become damaged after IR injury before 
cellular injury and morphological changes can be observed, especially in the RPTC 
[76]. Likewise, recent research has strongly suggested that preventing mitochondrial 
damage from occurring after an insult and/or promoting repair of damaged 
mitochondria can prevent maximal injury resulting from the insult and increase the 




Ischemia-Reperfusion Model of AKI 
Rodents, particularly rats and mice, are commonly used for renal IR experiments to 
mimic human AKI. After a surgical midline excision, through both skin and muscle 
layers, while the animal is under anesthesia, the renal artery or pedicle is located. The 
renal artery is clamped either bilateral or unilateral for a specific amount of time, 
depending on the specific model of AKI. After ischemia, the clamps are removed and 
blood flow is observed to reperfuse the kidney, as a color change will occur (Figure 
1.9). Experimental ischemia times can vary from one experimental study to the next 
while achieving the same final outcome changes (ex. BUN, SCr). This most likely 
stems from different core rodent body temperature maintained during surgery. Without 
maintaining a specific core body temperature, clamping/ischemia times must be 
greater than rodents with a maintained core body temperature [78-80]. In general, rats 
are less sensitive to IR injury and require longer ischemia times than mice, as bilateral 
clamping of rat renal pedicles typically needs 60 minutes to achieve the injury level of 
18-30 minutes of clamping in mice [79]. Cell death, altered renal tubule blood flow, 
loss of RPTC adhesion and cellular integrity, and lumen cast formation are all 





Figure 1.9: Representative images demonstrating induction of renal 
ischemia following by reperfusion. Adapted from [4]. 
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Biomarkers of AKI 
Novel AKI biomarkers have been researched heavily over the past decade. The earlier 
renal injury can be detected the earlier potential treatment options may be initiated for 
the patient, leading to better renal functional outcomes. Both urine and serum 
biomarkers could be easily tested in a hospital setting. Serum creatinine (SCr) and 
blood urea nitrogen (BUN) are two of the oldest and most common measurements for 
renal dysfunction in both a clinical and research setting [83]. However, both SCr and 
BUN have downfalls as a biomarker. The first is that increases in SCr and BUN may 
not be observed until days after an injury has occurred, yet, GFR is well-below normal 
[84]. This, in turn, could lead to an underestimated degree of injury, delayed 
treatment, and a failure to discontinue renal toxic medications. Second, SCr and BUN 
measurements can be altered by muscle mass, age, nutrition status, and medications 
[85]. An ideal biomarker would not change due to the above non-injury related factors. 
With the above limitations, there are now a multitude of new renal biomarkers being 
studied, with greater sensitivity and fewer alterations due to non-injury related 
changes in the patient. These biomarkers are being further studied to determine their 
practical use in a hospital setting [86] (Figure 1.10). The below paragraphs will focus 
on two specific biomarkers of kidney injury, neutrophil gelatinase-associated lipocalin 
(NGAL) and kidney injury molecule-1 (KIM-1), as these are two molecules we 
focused on in our research projects.  
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NGAL, also known as lipocalin-2, was originally found in neutrophils and has a 
molecular weight of 25-kDa [87]. NGAL is found in various epithelial cells within the 
kidney, trachea, lungs, stomach, and colon, and its function is to scavenge labile iron 
[88]. Labile iron is released from cellular organelles during an ischemic or septic 
injury, and can further cause oxidative stress after the ischemic injury has abated [89]. 
NGAL is highly upregulated following renal ischemia, and was found expressed in 
renal tubular cells in a mouse model of IR AKI [90, 91].  One of the first studies 
demonstrating the favorable biomarker profile of NGAL over SCr, was performed in 
2005, where in pediatric patients who had subclinical AKI expressed high NGAL 
levels before SCr increased by 1-3 days [16]. An interesting finding was NGAL could 
be tested for in the blood and/or urine [16]. Renal ischemia studies have revealed 
NGAL expression levels increase in proportion to renal injury severity and duration, 
with NGAL levels increasing as early as 1 hr after IR injury and up to 3 days before 
any clinically relevant SCr changes [90, 92-94]. A potential limitation of NGAL as a 
clinically relevant biomarker of AKI, is if the patient has a bacterial infection or 
sepsis. Because neutrophils release NGAL after activation during a bacterial systemic 
infection, the NGAL assay measurements become difficult to interrupt and distinguish 
between infection and AKI [95, 96]. However, Canada and Europe has approved 
NGAL for clinical use for patients with suspected AKI [92, 97, 98].  
KIM-1 is a conserved type-1 transmembrane glycoprotein that contains an 
immunoglobulin-like and glycosylated mucin domain [99]. KIM-1 protein is localized 
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to the renal proximal tubular cells, and is expressed at very low levels under non-
injured conditions [99]. However, following an ischemic or septic injury KIM-1 
expression rapidly increases significantly [100]. Unique to KIM-1, as a biomarker, is 
the specificity of demonstrating proximal tubule injury during AKI [99]. Following 
renal injury, the ectodomain of KIM-1 is cleaved and shed into the tubular filtrate 
within the lumen where it is excreted with the urine. Urine immunoassays were 
developed to test for KIM-1 ectodomain in high-risk patients for AKI, such as 
following cardiopulmonary bypass, cardiac catheterization, and ICU emergency 
surgery [101, 102]. KIM-1 recognizes phosphatidylserine and oxidized lipoprotein 
epitopes on the surface of apoptotic bodies that are found in the lumen following renal 
injury. Once recognized, KIM-1 helps clear the lumen debris by facilitating 
phagocytosis, which decreases an inflammatory response and helps prevent 
obstruction within the tubule [103, 104]. KIM-1 mRNA increases within 3 hr 
following renal IR injury and increased protein expression can be observed before 
changes in SCr and BUN [105, 106]. Because KIM-1 is found in the proximal tubules, 
the sensitivity for specifically denoting renal injury is higher than other biomarkers for 
AKI (Figure 1.10) [105]. However, a limitation of KIM-1 is that the receptor helps 
with repair processes, therefore finding increased KIM-1 in the urine may not help in 
identifying early AKI as the KIM-1 in the urine may be present due to the recovery 
phase. Recently, 32 urine biomarkers were studied following cardiac surgery for their 
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predictive value in determining AKI severity; the combination of IL-18 and KIM-1 





Figure 1.10: Biomarkers of AKI. Traditionally used markers, such as blood urea 
nitrogen (BUN) and creatinine (CR), are insensitive, nonspecific, and do not 
adequately differentiate between the different stages of AKI. A delay in diagnosis 
prevents timely patient management decisions, including administration of 
putative therapeutic agents. Urinary biomarkers of AKI will facilitate earlier 
diagnosis and specific preventative and therapeutic strategies, ultimately resulting 
in fewer complications and improved outcomes [3] 
36 
 
Pharmacological Treatment of AKI 
Currently, there is no effective pharmacological treatment for AKI. Therapeutic 
strategies for managing AKI involve maintaining proper fluid volume status, 
controlling disease states associated with renal damage, discontinuing renal toxic 
medications, and renal replacement therapy. Pharmacological agents have been 
studied in the literature and include vasoactive drugs (dopamine, fenoldopam, 
theophylline), anti-inflammatory drugs (aspirin, dexamethasone), and antioxidants (N-
acetylcysteine) [109-114]. Figure 1.11 shows recent novel therapeutic agents for the 
treatment of AKI (Figure 1.11) [115]. Developing a treatment option for AKI is 
difficult as there are multiple pathophysiological mechanism of injury occurring in 
parallel and in sequence [115]. Oxidative stress, disrupted cellular metabolism, 
mitochondrial bioenergetics dysfunction, inflammation, apoptosis, and necrosis occur 
simultaneously at the initiation of the injury and progression to AKI [116]. Because of 
the aforementioned multitude of altered cellular and mitochondrial process, future 
pharmacological drug trials will conceivably focus on a multi-targeted approach 
possibly with more than one active drug being tested. The logic behind this approach 
is to restore multiple known dysfunctional pathways after AKI, as single agent 





Figure 1.11: Novel therapeutic agents for acute kidney injury. 






Mitochondria are subcellular organelles that generate the energy-rich molecule, ATP, 
through oxidative phosphorylation, which regulates cellular metabolism and 
homeostasis. Beyond ATP production, mitochondria are involved in a host of other 
pathways, including, calcium storage and signaling, fatty acid oxidation, ROS 
generation and signaling, citric acid cycle, regulating programmed cell death, initial 
steroid hormone synthesis, heme synthesis, and heat production.  
 
Mitochondrial Structure 
The mitochondria is a membrane-bound organelle consisting of two membrane layers 
made up of phospholipid bilayers, the outer mitochondrial membrane (OMM) and the 
inner mitochondrial membrane (IMM). The OMM is a selectively permeable 
membrane containing porins, channel proteins, for transporting various essential 
molecules into the mitochondria. Because the IMM is much larger than the OMM, the 
IMM is able to fit inside the OMM because it contains membrane folds called cristae, 
and is a much more selective membrane barrier than the OMM [117]. The nature of 
the mitochondrial structure consisting of the OMM and IMM helps form four different 
areas within the mitochondria. The first consists of the OMM and the transport 
channel proteins and some metabolic enzymes. The second, is the intermembrane 
space, the space between the OMM and IMM, which maintains a proton gradient for 
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the proper function of the electron transport chain (ETC). The third is the IMM, where 
the ETC components are located, including, Complex 1-IV and ATP synthase. The 
fourth is the mitochondrial matrix where many metabolic pathways occur, including 
the citric acid cycle and fatty acid oxidation. The mitochondrial matrix contains the 
mitochondrial DNA (mtDNA), which is circular double stranded DNA located in the 
mitochondria and separate from the nuclear DNA. The mitochondrial matrix also 
contains the enzymes and ribosomes for mtDNA transcription and mitochondrial-
encoded protein translation [117, 118].  
 
Mitochondrial DNA 
The mitochondria contain the only other source of DNA within the cell besides the 
eukaryotic nucleus. mtDNA are maternally inherited DNA that are packaged inside 
the inner mitochondrial membrane, usually along the cristae, in nucleoids [119, 120]. 
These nucleoids consist of mtDNA and specific mtDNA proteins required for stability, 
replication, transcription, repair, and packaging [121]. mtDNA is circular double 
stranded DNA containing 37 genes that encodes 13 subunits of the mitochondrial 
oxidative phosphorylation system, 22 tRNAs, and 2 rRNAs. The other ~1500 
mitochondrial proteins are transcribed from nuclear DNA [122]. The exact number of 
mtDNA molecules per cell varies wildly from hundreds to thousands based on tissue 
specific needs [123]. The kidney is the second highest mitochondrially dense organ 
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behind the heart, although the mitochondria within the proximal convoluted tubules 





Because the mitochondria play such a critical role in most cells life cycle, the proper 
functioning of the mitochondria is essential for a healthy cell. Mitochondrial 
homeostasis is the termed used for quality control over generating new mitochondria 
(mitochondrial biogenesis) or programmed removal of damaged mitochondria 
(mitophagy), as well as mitochondrial dynamics (fission and fusion) [125, 126]. 
Mitochondrial dynamics alters the morphology and consists of the interplay between 
two distinctly different process, fission and fusion. Mitochondrial fission is the 
process of dividing mitochondria into smaller mitochondrion. Fission requires the 
cytosolic GTPase dynamin-related protein 1 (Drp1) and OMM located mitochondrial 
fission 1 protein (Fis1). Mitochondrial fusion is the joining of separate mitochondria 
to form branched and elongated mitochondrial networks. Fusion requires the OMM 
located mitofusins 1 and 2 (Mfn1 and Mfn2) and the IMM located optic atrophy 1 
(OPA1). Fusion and fission occur constantly throughout the cells life cycle and this 
interplay can determine the energy status of the cell [127, 128]. Mitochondrial 
mitophagy is the way in which the cell is able to degrade damaged or dysfunctional 
mitochondrial by way of lysosomal digestion. Mitophagy is regulated through the 
OMM located PTEN-induced putative kinase 1 (PINK1) and the cytosolic E3 







Figure 1.12: Mitochondrial Life Cycle. Mitochondrial homeostasis is a 
multifactorial process governed by MB, fission/fusion and mitophagy. PGC-1α 
activates nuclear respiratory factor 1 (Nrf1) and nuclear respiratory factor 2 (Nrf2) 
to coordinate the expression of nuclear genes required for MB. PGC-1α also 
activate mitochondrial transcription factor A (TFAM) and mitochondrial 
transcription factor B (TFBM), which regulate the transcription of genes encoded 
by mtDNA. Mitochondria undergo cycles of fusion, which is mediated by 
mitofusin (Mfn) 1, Mfn2 and optic atrophy protein (Opa1). Fission is mediated by 
dynamin-related protein 1 (Drp1) and fission 1 (Fis1). Fission also promotes the 
isolation of damaged mitochondria for selective mitochondrial degradation, a 
process called mitophagy. Mitophagy involves the mitochondrial depolarization, 
accumulation of putative kinase protein kinase 1 (Pink1) on the mitochondrial 
membrane, recruitment of Parkin, which targets the mitochondria to the 
autophagosome through the ubiquitination of mitochondrial proteins. Assembly of 
the phagosome involves beclin-1, p62 and conjugation of microtubule-associated 





Mitochondrial biogenesis (MB) is broadly defined as the cell’s pathway to generate 
new functioning mitochondria. MB can increase preexisting mitochondrial mass and 
copy number and therefore, has the potential to increase energy production by way of 
ATP synthesis. MB occurs under physiological conditions, but can be highly induced 
due to various extracellular stressors, exercise, calorie insufficiency, and low body 
temperatures [130, 131]. The master regulator of MB is the nuclear transcriptional 
coactivator peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1α). 
The PGC-1 family of transcriptional co-activators also includes PGC-1β and PGC-1-
related coactivator (PRC) that can also regulate MB. However, PGC-1α has been 
shown to be abundantly expressed in tissues with high-energy demands, such as the 
heart, skeletal muscle and the kidney. Increased PGC-1α or increased activity of PGC-
1α increases MB specific nuclear- and mitochondrial-encoded proteins required for the 
generation of new mitochondria or increased mitochondrial mass [132, 133]. PGC-1α 
enhances the following transcription factors, PPARs (PPARα, PPARδ, PPARγ), 
estrogen related receptors (ERRα, ERRβ, and ERRγ), nuclear respiratory factors 
(NRF-1 and NRF-2), and FOXO3 (forkhead box protein O3) [134, 135]. PGC-1α, like 
its other PGC-1 family, contains an N-terminal activation domain consisting of 
leucine-rich LXXLL motif that mediates its activity with other nuclear transcription 
factors. As PGC-1α is a co-activator, it does not bind DNA but enhances the activity 
of other transcriptional factor and their associated-protein binding complexes.  
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NRF Transcriptional Regulation of Mitochondrial Biogenesis 
NRF-1 and NRF-2 are nuclear transcription factors that upregulate specific nuclear-
encoded mitochondrial genes, and are enhanced by PGC-1α. NRF-1 increases the 
expression of various mitochondrial-related genes, including mitochondrial ETC 
complex components (ETC complex subunits, cytochrome C), mtDNA transcription 
and translation (transcription factor A, TFAM), and mitochondrial protein transport 
and assembly (TOM20, COX17) [136, 137]. NRF-2 is also a transcriptional factor for 
other mitochondrial related targets, including mitochondrial respiration (subunit IV of 
cytochrome c oxidase), mitochondrial import proteins (Tom20, Tom70), and mtDNA 
transcription (TFAM) [136]. The importance of properly functioning mitochondrial 
regulation can be found in NRF-1 and NRF-2 knockout mice, as mice with both NRFs 





Mitochondrial Biogenesis in Renal Injury 
As mentioned previously, the renal proximal tubule epithelial cells require lots of 
oxygen to power oxidative phosphorylation, which supplies their high energy 
requirements for the various transport processes that are constantly active for filtering 
the blood. The mitochondrial density within RPTC is one of the highest of any organ 
cell type in the body; hence, any injury that causes mitochondria dysfunction will 
cause detrimental affects to the RPTC and ultimately kidney dysfunction. Acute 
oxidant injury has been shown to cause mitochondrial dysfunction in RPTC, by 
decreasing ATP levels and oxygen consumption rate in the mitochondria [140, 141]. 
Interestingly, overexpression of PGC-1α after oxidant injury in RPTC increased 
mitochondrial specific proteins, ATP levels, and mitochondrial oxygen consumption 
(Figure 1.13) [6]. In two experimental models of AKI, IR- and sepsis-induced, PGC-
1α mRNA is rapidly downregulated within 3 hr of initiated injury. This rapid 
regulation of mitochondrial biogenesis after AKI, demonstrates the potential to target 







Figure 1.13: Overexpression of PGC-1α after oxidant injury restored 
mitochondrial protein expression (A) as well as total cellular ATP (B) and 
basal (C) and uncoupled (C) oxygen consumption in RPTC exposed to 




Pharmacological Activation of Mitochondrial Biogenesis 
Because the mitochondria play such a big role in RPTC physiology and 
pathophysiology as mentioned above, the identification of a pharmacological agent 
that would activate MB would be a great therapeutic strategy for prevention of RPTC 
injury or increasing repair following AKI. For this reason, pharmacological agents that 
control PGC-1α have been a central focus in our lab, as well as many others. Using 
pharmacological agents to modulate upstream MB pathways such as AMP kinase, 
sirtuins, cyclic AMP and GMP, B2 receptor, and the 5-HT1F receptor has shown 
promise in activating MB [144-151]. Figure 1.14 showcases the multitude of pathways 







Figure 1.14: Pharmacological Activation of MB. MB is a complex process 
controlled by the transcriptional regulator, PGC-1α. PGC-1α expression and 
activity is regulated by a variety of pathways including receptor tyrosine kinases, 
G-protein coupled receptors (GPCR), naturetic peptide receptors, cyclic 




Likewise, targeting negative regulators of MB would be of therapeutic benefit. Instead 
of increasing an activation pathway (as discussed above), an inhibition or blockade of 
physiological or pathological signaling that negatively regulates PGC-1α or other MB 
pathways would conceivably be of benefit before, during, or after AKI has occurred. 
Negative regulation of MB has been observed in multiple forms of AKI, including IR 
injury, sepsis, gentamycin toxicity, and folic acid nephropathy, where mitochondrial 
gene targets and proteins are downregulated rapidly after injury [126, 142, 143, 153-
156]. Negative regulation of MB does not only occur in injured states, but has also 
been observed to occur in an age-associated manner [157, 158]. Multiple negative 
regulator pathways have been studied including the transcription factors, receptor-
interacting protein 140 (RIP140), hypoxia-inducible factor 1-α (HIF-1α), and 
mitochondrial transcription termination factor 3 (MTERF3) [132]. The pro-
inflammatory cytokine tumor necrosis factor alpha (TNF-α) has been demonstrated to 
downregulate MB through an eNOS dependent manner and cause mitochondrial 
dysfunction by decreasing mitochondrial proximity with sarcoplasmic reticulum. [159-
161]. The mitogen-activated protein kinase (MAPK), ERK1/2 (extracellular signal-
regulated kinases 1/2), when activated, has been shown to reduce mitochondrial basal 
respiration and ATP production, reduce uncoupled oxygen consumption, disrupt 
mitochondrial membrane potential, initiate iron-induced mitochondrial swelling, and 
decrease MB targets [142, 162-167]. The remainder of the dissertation will focus on 
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ERK1/2 signaling and inhibition of ERK1/2 activation following multiple models of 





Intracellular signaling is an important and complex cellular pathway by which all 
different cell types respond to extracellular stimuli and events. The purpose of 
intracellular signaling is to allow the cell to respond and adjust to environmental 
factors and extracellular stimuli presented to the cellular surface. In this way the cell 
can upregulate or downregulate certain signaling pathways that would potentially be 
more beneficial for the cell in their current environment. These intracellular signaling 
events can occur rapidly, which allows the cell to respond in a timely manner to adapt 
and thrive. Examples of changes within the cell that could occur are alterations in gene 
transcription, protein expression, post-translational modifications, protein 
translocation, enzyme activity rates, and changes in cellular metabolism [168, 169].  
 
Extracellular stimuli and/or environmental factors have the ability to stimulate various 
receptors on the cell surface causing activation of the receptors through ligand binding 
and/or non-binding (temperature) of the receptor. These receptors could be ion 
channel-linked (ex. 5-HT receptor), enzyme-linked (ex. receptor tyrosine kinase), and 
G-protein-coupled (ex. β2-adrenergic receptor). Once activated the receptors stimulate 
intracellular targets by way of recruitment and adapter proteins that are usually located 
near the cell surface from the cytosolic side along the membrane [170, 171]. 
Depending on the receptor type and activation, the adaptor proteins stimulate a 
signaling cascade where one activation leads to another activation in a stepwise 
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manner. One of the most well-known and studied intracellular signaling cascade is the 
mitogen-activated protein (MAP) kinase pathway. The classical MAP kinases are Jun 
N-terminal kinase (JNK), p38, and ERK. The ERK family is one of the best-
characterized family of MAP kinases, specifically ERK1 and ERK2 [172].  
 
Extracellular Signal-Regulated Kinase 1/2  
ERK1/2 was found to become highly phosphorylated by addition of epidermal growth 
factor (EGF) and platelet-derived growth factor (PDGF) to developing chicken 
embryos [173]. At the time (1983), the authors did not know they were studying 
ERK1/2 just proteins of 40 and 42 kDa [173]. ERK1/2 becomes phosphorylated 
through growth factor stimulation because once bound to the receptor, a signaling 
cascade begins and preceding in a step-wise manner until phosphorylation of ERK1/2.  
Stimulation of receptor tyrosine kinases (RTKs) causes dimerization of the receptor, 
and allows autophosphorylation to occur [174]. The adapter protein growth factor 
receptor-bound protein 2 (Grb2) can now bind to the intracellular phosphorylated 
portion of the RTK, and recruits Son of Sevenless (Sos). This Grb2 and Sos complex 
allows for inactive Ras GTPases to locate to the activated RTK [175]. The three 
subfamily of Ras proteins that activate the ERK1/2 signaling cascade are H-Ras, K-
Ras, and N-Ras. Inactive Ras is Ras bound with GDP. Upon association with Grb2 
and Sos complex, Ras releases GDP and binds GTP, which promotes conformational 
changes to Ras. These changes create a better surface for protein-protein interactions, 
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which leads to activation of various effector proteins (Raf, phospholipase C) from the 
cell surface and downstream signaling throughout the cytosol, mitochondria, and 
nucleus [172].  
 
The main effector, with respect to ERK1/2 signaling, is the Raf family of kinases. 
There is A-Raf, B-Raf, and C-Raf, which are serine/threonine kinases. Once Ras has 
become activated, Rafs phosphorylate and activate MEK1 and MEK2 (MEK1/2) [176, 
177]. Raf kinase localization and activity are dependent on the multiple 
conformational changes and phosphorylations they can undergo [177, 178]. For C-Raf, 
phosphorylation at Ser338 and Tyr341 are needed for Raf kinase activity. B-Raf has a 
higher basal kinase activity than C-Raf because B-Raf contains a phosphomimetic at 
position 448, which mimics C-Raf phosphorylation at Tyr341. Raf kinases (and other 
MAP kinase kinases) phosphorylate MEK1 and MEK2 on Ser218 and Ser222, and 
both amino acids becoming phosphorylated are required for full activation [172, 179]. 
MEK1/2, once activated, can phosphorylate ERK1 and ERK2, which are the only 






Figure 1.15: Schematic Representation of the Ras-Raf-MEK-ERK1/2 
MAP kinase pathway. GF, growth factor; RTK, receptor tyrosine kinase. 
Adapted from [5]. 
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ERK1 is phosphorylated at Thr202 and Tyr204 and ERK2 is phosphorylated at 
Thr183 and Tyr185, and both phosphorylation sites are required for maximal activity 
of ERK1/2 [180, 181]. ERK1 and ERK2 contain ~85% sequence identity, 100% 
similar catalysis and docking residues, are activated from identical stimuli, perform 
similar downstream functions inside the cell, and are co-expressed in almost all cell 
types [182-185]. However, ERK2 knockout mice are embryonic lethal, whereas ERK1 
knockout mice are not and are fertile, pointing to ERK2 playing a more essential role 
in mouse embryo development [186-188]. Contradicting this ERK specific 
developmental assumption, is a study by Fremin et al., which demonstrated mice 
embryos developed normally in ERK2 deficient embryos by increasing ERK1 by an 
Erk1 transgene [189]. Therefore, ERK1 and ERK2 may be functionally repetitive 
during mouse developmental stages as well as in a mature mouse, and any knockdown 
of one kinase, ERK1 or ERK2, led to observable effects merely because of a decrease 
in total kinase protein levels [184, 189, 190]. 
 
ERK1/2 can be anchored in the cytoplasm by various proteins, including MEKs and 
MAP kinase phosphatase 3 (MKP-3). However, ERK1/2 can translocate into the 
nucleus by way of passive diffusion, as the size of ERK1 (44 kDa) and ERK2 (42-
kDa) is small enough to not require ATP or specialized protein transporters [191, 192]. 
This translocation process is dynamic and ERK1/2 do not contain nuclear export 
sequence, but rather ERK2 is exported by both energy- and carrier-independent 
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mechanisms, mediated in part by the exportin, Exportin 1 (XPO1 or CRM1) and the 
nuclear pore complex, specifically the nucleoporin, Tpr [193-196].   
Extracellular stimuli can activate ERK1/2 in minutes which can be critical for the cell 
(and tissue/organ) depending on the biological response required to initiate. ERK1/2 
has been shown to be involved with cell survival, cell death, differentiation, 
proliferation, migration, transcription, and translation among others [172, 197, 198]. 
To accomplish the above-mentioned biological responses, ERK1/2 phosphorylates 
various cellular substrates, and these substrates perform downstream cellular functions 
that ultimately provide the response for the specific stimulus. Currently, ERK1/2 was 
found to have 659 direct phospho-site targets on various substrates [199]. Among 
those substrate targets of ERK1/2 are upstream proteins involved in ERK1/2 
activation, including Sos1, Raf, and MEK1. Interestingly, ERK1/2 phosphorylation of 
these upstream proteins decreases its own activation signal, by diminishing each 
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Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor γ 






Previous studies have shown that extracellular signal-regulated kinase 1/2 (ERK1/2) 
directly inhibits mitochondrial function during cellular injury. We evaluated the role 
of ERK1/2 on the expression of peroxisome proliferator-activated receptor γ 
coactivator-1α (PGC-1α) gene, a master regulator of mitochondrial function. The 
potent and specific MEK1/2 inhibitor trametinib rapidly blocked ERK1/2 
phosphorylation, decreased cytosolic and nuclear FOXO3a/1 phosphorylation, and 
increased PGC-1α gene expression and its downstream mitochondrial biogenesis 
(MB) targets under physiological conditions in the kidney cortex and in primary renal 
cell cultures. The epidermal growth factor receptor (EGFR) inhibitor erlotinib blocked 
ERK1/2 phosphorylation and increased PGC-1α gene expression similar to treatment 
with trametinib, linking EGFR activation and FOXO3a/1 inactivation to the down-
regulation of PGC-1α and MB through ERK1/2. Pretreatment with trametinib blocked 
early ERK1/2 phosphorylation following ischemia/reperfusion kidney injury and 
attenuated the down-regulation of PGC-1α and downstream target genes. These results 
demonstrate that ERK1/2 rapidly regulates mitochondrial function through a novel 
pathway, EGFR/ERK1/2/FOXO3a/1/PGC-1α, under physiological and pathological 
conditions. As such, ERK1/2 down-regulates mitochondrial function directly by 






ERK1/2 is a major player in various cell signaling pathways, including proliferation, 
differentiation, senescence, cell injury and recovery, and apoptosis. ERK1/2 becomes 
activated through a variety of extracellular stimuli, including receptor tyrosine kinases 
(RTK) such as the epidermal growth factor receptor (EGFR), which leads to the 
activation of mitogen-activated protein kinase kinase (MEK) (1,2). EGFR agonists 
activate intrinsic tyrosine kinase activity within the cytoplasmic domain of the receptor, 
initiating the recruitment of Ras, a GTPase, which allows for interaction with 
downstream effectors, including the Raf protein kinases. Raf phosphorylates MEK1/2, 
which phosphorylates ERK1/2. ERK1/2 is thought to be the only substrate for MEK1/2 
phosphorylation, which has allowed for MEK1/2 inhibitors to be used specifically for 
ERK1/2 inactivation (3,4).  
ERK1/2 is also activated by cell stressors, including reactive oxygen species (ROS). 
Utilizing H2O2 injury in human renal cells, ERK1/2 inhibition was shown to decrease 
necrosis and apoptosis (5), while in a cisplatin-induced cell injury model ERK1/2 
inhibition reduced caspase 3 activation and apoptosis (6). In renal proximal tubular cells 
(RPTC), phosphorylated ERK1/2 was shown to reduce mitochondrial respiration and 
ATP production by decreasing complex I electron transport chain activity in response to 
tert-butyl hydroperoxide (TBHP), a model oxidant (7). Nowak, et al., also showed that 
expression of a constitutively active MEK1 increased ERK1/2 activation and decreased 
basal and uncoupled oxygen consumption, a measure of electron transport chain activity 
(7). Zhuang, et al., demonstrated that H2O2 treatment of RPTC led to a high level of 
ERK1/2 phosphorylation and loss of mitochondrial membrane potential (MMP) which 
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was attenuated by treating with a MEK/ERK1/2 inhibitor. Finally, Fe2+-induced 
mitochondrial swelling was shown to occur through activation of the ERK1/2 pathway 
(8). These findings illustrate that ERK1/2 decreases mitochondrial function in response 
to injury. 
The kidney is a high-energy consuming organ and its cells have an abundance of 
mitochondria to meet ATP demand, especially within the proximal tubules (9). Previous 
studies demonstrated that rapid and persistent disruption of mitochondria homeostasis is 
an important contributor to the pathology of renal ischemia/reperfusion (IR) injury 
(10,11). PGC-1α is thought to be the master regulator of mitochondria biogenesis (MB) 
and is enriched in tissues with high metabolic demand, such as the heart, skeletal 
muscle, and kidney (12,13). The role of ERK1/2 activation and subsequent regulation of 
PGC-1α and downstream targets involved in mitochondrial homeostasis and 
dysfunction remains limited.  
 
Physiological and pathological stimuli, such as exercise, caloric restriction, hypoxia, 
sepsis, and ischemia/reperfusion (IR) are known to alter PGC-1α expression (9,14).  IR-
induced renal injury rapidly suppresses MB, PGC-1α and its direct downstream targets 
at the transcriptional and protein level (10,11,13). However, the mechanism(s) by which 
PGC-1α is transcriptionally suppressed after injury has not been determined. Therefore, 
we examined the role of ERK1/2 in renal PGC-1α transcription under physiological and 
pathophysiological conditions in primary cultures of RPTC and in the renal cortex of 
mice. We determined that ERK1/2 regulates PGC-1α in RPTC and in the renal cortex of 
mice at a physiological level through phosphorylation of the transcription factors 
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FOXO3a/1. EGFR was found to be the upstream activator of ERK1/2 under basal 
conditions, negatively regulating PGC-1α transcription. Finally, under the 
pathophysiological condition of IR-induced AKI in mice, ERK1/2 activation was 
responsible for the initial decrease in PGC-1α mRNA expression and the decrease in 
kidney function as measured by serum creatinine. By inhibiting ERK1/2 activation we 
attenuated the early decrease in PGC-1α and prevented the decrease in kidney function. 
This research is significant because PGC-1α is the key regulator for MB and by 
sustaining mitochondrial homeostasis ERK1/2 inhibition may be a potential therapeutic 
to prevent further injury and/or increase recovery where early mitochondrial 






ERK1/2 Inhibition Increases PGC-1α and MB Proteins mRNA in RPTC. 
To test the hypothesis that ERK1/2 regulates PGC-1α and MB at a physiological level, 
we utilized the pharmacological MEK1/2 inhibitor trametinib and primary cultures of 
rabbit RPTC. Trametinib has been well-characterized as a potent and specific inhibitor 
of MEK1/2 with an IC50 of 0.92 to 3.4 nM in various cell lines and shows limited 
inhibitory activity against at least 98 other kinases (15,16). RPTC were treated with 0.3, 
1, or 10 nM trametinib, and at 10 nM ERK1/2 phosphorylation was completely 
inhibited after 4 hr (Figure 2.1A). Trametinib (10 nM) completely inhibited ERK1/2 
phosphorylation within 10 min and continued to inhibit for 24 hr (data not shown) 
without altering total ERK1/2 (Figure 2.1A). PGC-1α mRNA expression increased 1.8-
fold at 1 hr and 2.8-fold at 4 hr before decreasing to control levels at 24 hr after 
trametinib exposure (Figure 2.1B). The increase in PGC-1α mRNA was linked to 
increased nuclear-encoded mediators of MB and gene targets of PGC-1α, including 
mitochondrial transcription factor A (TFAM), nuclear respiratory factor-1 (NRF1), and 
NADH Dehydrogenase (Ubiquinone) Fe-S Protein 1 (NDUFS1) at 1, 4 and 24 hr after 
trametinib treatment (Figure 2.1C-E). These results reveal that ERK1/2 represses PGC-
1α mRNA expression and its downstream target genes under physiological conditions 
and that inhibition of ERK1/2 activation results in a rapid induction of PGC-1α mRNA 






Figure 2.1: ERK1/2 inhibition increases levels of PGC-1 and downstream 
targets of MB mRNA. A, immunoblotting analysis of phosphorylated ERK1/2 (p-
ERK1/2) in RPTC in response to increasing concentrations of trametinib at 4 h and 
increasing time of exposure to 10 nM trametinib. Veh, vehicle; MW, molecular 
weight. B–E, mRNA expression of PGC-1, TFAM, NDUFS1, and NRF1 at 1, 4, and 
24 h after treatment with 10 nM trametinib. Data are represented as mean S.E., n > 
5. Different superscripts indicate statistically significant differences (p < 0.05). 
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ERK1/2 Regulates PGC-1α Through Phosphorylation of FOXO3a Independent of 
p38 and AKT Kinases in RPTC. 
We analyzed the phosphorylation levels of FOXO3a in RPTC 30 min after trametinib 
treatment since FOXO3a is a direct transcriptional regulator of PGC-1α (17-19). 
Phosphorylation of the ERK1/2 phosphorylation site, serine 294, on FOXO3a decreased 
54% at 30 min in RPTC treated with trametinib (Figure 2.2A-B). Other kinases, such as 
p38 and AKT are known to target FOXO3a for phosphorylation (20,21); however, p38 
and AKT phosphorylation did not change in the presence of trametinib (Figure 2.2C).  
To exert its transcriptional effects, FOXO3a shuttles between the cytosol and the 
nucleus (22). Phosphorylation of FOXO3a inactivates the protein by preventing it from 
entering the nucleus and increases the rate of export from the nucleus to the cytosol 
where it may be degraded (23). Therefore, phosphorylation of FOXO3a decreases its 
ability to bind to promoters and increase gene expression (20,23,24). Nuclear 
phosphorylated FOXO3a decreased 60% in the trametinib-treated RPTC at 30 min with 
no alteration in total FOXO3a nor the loading control, lamin B1 (Figure 2.2D-E). In 
summary, phosphorylated ERK1/2, but not AKT or p38, phosphorylates FOXO3a, 
which inactivates FOXO3a in the nucleus, and prevents FOXO3a from increasing PGC-
1α expression physiologically. This dynamic control of FOXO3a by ERK1/2 regulates 







Figure 2.2: ERK1/2 regulates PGC-1 through phosphorylation of FOXO3a 
independent of p38 and AKT kinases in RPTC. A, representative immunoblot of 
pFOXO3a after 10 nM trametinib treatment in RPTC. p, phosphorylated; Veh, vehicle; 
MW, molecular weight. B, densitometry analysis of phosphorylated FOXO3a, with -
actin as loading control. C, densitometry analysis of p38 and AKT kinases. D, 
representative immunoblot of phosphorylated and total FOXO3a in the nucleus. E, 
densitometry analysis of phosphorylated FOXO3a in the nucleus following ERK1/2 
inhibition. Data are represented as mean S.E., n > 5. Different superscripts indicate 
statistically significant differences (p < 0.05). 
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EGFR Inhibition Increases PGC-1α mRNA Expression by Preventing ERK1/2 
Activation in RPTC.  
EGFR is known to regulate the activity of the ERK1/2 signaling cascade (1,25,26).  To 
determine whether ERK1/2 inhibition of PGC-1α mRNA was mediated by the EGFR in 
RPTC, we utilized the EGFR inhibitor erlotinib, a direct inhibitor of the intracellular 
kinase domain of the EGFR that prevents autophosphorylation and signal transduction 
(26). Within 1 hr of erlotinib treatment (100 nM and 1 µM), ERK1/2 phosphorylation 
was blocked without a change in total ERK1/2 protein and remained decreased 4 hr post 
treatment (Figure 2.3A). PGC-1α mRNA expression was increased at 4 hr by 2.4- and 
2.8-fold in the 100 nM and 1 µM erlotinib groups, respectively (Figure 2.3B). NRF1 
was also up 2.4-fold by 4 hr after EGFR inhibition (Figure 2.3C). We conclude that 
EGFR inhibition with erlotinib leads to an upregulation of PGC-1α mRNA through 
inactivation of ERK1/2. It should be noted that the 4 hr increases in PGC-1α mRNA 
expression are very similar to the increases observed using trametinib (Figure 2.1B). In 
summary, under physiological conditions the activation of the EGFR/ERK1/2/FOXO3a 




  Figure 2.3: EGFR inhibition increases PGC-1 mRNA expression by preventing 
ERK1/2 activation in RPTC. A, representative immunoblot of phosphorylated 
ERK1/2 after treatment with increasing concentrations of erlotinib 
(ErL) at 1 and 4 h in RPTC. p, phosphorylated; Veh, vehicle. B and C, mRNA 
expression of PGC-1 (B) and NRF1 (C) following increasing concentrations of 
erlotinib at 4 h. Data are represented as mean  S.E., n > 5. Different superscripts 
indicate statistically significant differences (p <0.05). 
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ERK1/2 Physiologically Regulates PGC-1α Expression and Protein by Altering 
FOXO1 Phosphorylation in the Mouse Kidney. 
Our laboratory and others have previously reported that a 1 mg/kg dose of trametinib 
inhibits ERK1/2 phosphorylation in mice (16,27). We verified that trametinib (1 mg/kg, 
i.p.) inhibited ERK1/2 phosphorylation at 4 hr post-injection in the renal cortex with no 
change to total ERK1/2 protein (Figure 2.4A). PGC-1α mRNA expression in the renal 
cortex increased 1.5-fold 4 hr after ERK1/2 inhibition, corresponding with the 
observations made in vitro (Figure 2.4B). Likewise, targets of PGC-1α were also 
upregulated at 4 hr with NRF1 mRNA elevated by 1.8-fold and TFAM mRNA up 1.2-
fold (Figure 2.4C).  Cytochrome c oxidase I (COX1) mRNA, a mitochondrial encoded 
gene, one of the subunits of respiratory complex IV, was also upregulated 1.4-fold 
following ERK1/2 inhibition with trametinib (Figure 2.4C). The increase in MB gene 
expression due to ERK1/2 inhibition resulted in increases in PGC-1α and TFAM 
proteins of 1.6-fold and 1.3-fold, respectively, at 4 hr in the trametinib group (Figure 
2.4B, D-E). 
After failing to detect FOXO3a in the mouse renal cortex (data not shown), we 
examined FOXO1. FOXO3a and FOXO1 are similar transcription factors and share 
overlapping activities, including regulating PGC-1α (20). FOXO1 phosphorylation at 
the phosphorylation site, serine 329, was decreased in the trametinib group 
(28,29)(Figure 2.5A-B). Total FOXO1 protein did not change in response to ERK1/2 
inhibition (Figure 2.5A). Neither AKT and p38 phosphorylation nor total AKT and p38 
proteins changed in the trametinib group (Figure 2.5C). Trametinib treatment decreased 
nuclear phosphorylated FOXO1 to total FOXO1 32%, 4 hr after trametinib (Figure 
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2.5D-E). FOXO1 mRNA was also upregulated at 4 hr post ERK1/2 inhibition (Figure 
2.5F). Further evidence that ERK1/2 inhibition results in increased FOXO1 gene 
transcription was revealed by increases in catalase and mitochondrial superoxide 
dismutase 2 (SOD2), two genes regulated by FOXO1 (Figure 2.5F) (30,31). We 
conclude that ERK1/2 regulates the activity of FOXO1 within the nucleus and controls 
the basal level of PGC-1α mRNA and subsequent PGC-1α protein levels, as well as 





  Figure 2.4: ERK1/2 physiologically regulates PGC-1 expression and protein in 
mouse kidney. A, representative immunoblot of phosphorylated ERK1/2 after 
treatment with trametinib in mouse kidney cortex. p, phosphorylated; MW, 
molecular weight. B, representative immunoblot of PGC-1 and TFAM proteins after 
treatment with trametinib in the kidney cortex. The black line represents the splicing 
of the blot from the same membrane. C, mRNA expression of PGC-1, NRF1, 
TFAM, and COX 1 following trametinib administration at 4 h. D and E, 
densitometry analysis of PGC-1 (D) and TFAM (E) protein at 4 h following 
trametinib. Data are represented as mean S.E., n > 5. Different superscripts indicate 




  Figure 2.5: FOXO1 phosphorylation in the cortex and nuclear phosphorylation 
decrease after ERK1/2 inhibition. A, representative immunoblot of 
phosphorylated FOXO1 and ERK1/2, AKT, and p38 kinases following trametinib 
administration. p, phosphorylated; MW, molecular weight. B, densitometry analysis 
of phosphorylated FOXO1 when compared with total FOXO1. C, densitometry 
analysis of phosphorylated AKT to total AKT, and phosphorylated p38 to total p38 
after trametinib treatment. D, representative immunoblot of nuclear phosphorylated 
FOXO1 and ERK1/2 after trametinib treatment in mouse kidney cortex. E, 
densitometry analysis of phosphorylated FOXO1 when compared with total FOXO1 
after inhibition of ERK1/2 in the nucleus. F, mRNA expression of FOXO1, SOD2, 
and catalase at 4 h following trametinib administration. Data are represented as 
mean  S.E., n > 4. Different superscripts indicate statistically significant differences 
(p < 0.05). 
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ERK1/2 Inhibition During AKI Attenuates an Increase in Serum Creatinine and 
Decreases in PGC-1α and NRF1 Expression. 
To examine the role of ERK1/2 on PGC-1α in the renal cortex under injurious 
conditions, we pretreated mice with trametinib or vehicle for 1 hr and then subjected 
mice to bilateral IR surgery or sham surgery for 18 min to induce AKI and kidneys were 
collected 3 hr later. IR-induced AKI decreases PGC-1α mRNA expression, as well as 
other mitochondrial genes and proteins (32). Trametinib prevented the increase in 
ERK1/2 phosphorylation following the IR (Figure 2.6A). PGC-1α mRNA decreased 
41% in IR mice after 3 hr and trametinib attenuated this decrease (Figure 2.6B). 
Interestingly, trametinib pretreatment increased NRF1 expression following IR 
compared to sham, whereas IR alone resulted in 13% decrease in NRF1 compared to 
sham (Figure 2.6B). At the protein level both PGC-1α and TFAM proteins increased 
1.7- and 2.4-fold, respectively (Figure 2.6C-D).  
Serum creatinine, a marker of renal dysfunction increased 4-fold in the IR group at 3 hr 
and was attenuated in the trametinib pretreatment group (Fig 6E). We demonstrate that 
by inhibiting ERK1/2 phosphorylation prior to inducing IR AKI we attenuated the 
decreases in PGC-1α and NRF1 mRNA, as well as increasing mitochondrial related 
proteins PGC-1α and TFAM 3 hr post-surgery. By maintaining mitochondrial function 




  Figure 2.6: ERK1/2 inhibition during AKI attenuates an increase in serum 
creatinine and increases PGC-1 and TFAM proteins. A, representative 
immunoblot of phosphorylated ERK1/2, total ERK1/2, TFAM, and PGC-1 
following IR AKI. p, phosphorylated; MW, molecular weight. B, mRNA expression 
of PGC-1 and NRF1 following IR AKI at 3 h after IR in the kidney cortex. C and D, 
densitometry analysis of PGC-1 (C) and TFAM (D) proteins following 3 h IR. E, 
serum creatinine was assessed 3 h after IR AKI. Data are represented as mean S.E., 
n > 5. Different superscripts indicate statistically significant differences (p < 0.05). 
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Erlotinib Blocks ERK1/2 Phosphorylation in Naïve Mice and Following IR, 
Preventing Decreases in PGC-1α and NRF1 Expression. 
To elucidate the role of EGFR on ERK1/2 and PGC-1α and MB genes in the renal 
cortex, erlotinib (50 mg/kg i.p.) was administered to naïve mice (33). Erlotinib 
decreased ERK1/2 phosphorylation by 45% in the kidney cortex 4 hr after 
administration (Figure 2.7A-B). Mice given erlotinib had 1.3-fold higher PGC-1α 
mRNA and 1.4-fold higher FOXO1 mRNA expression (Figure 2.7C). To elucidate if 
the EGFR is the upstream receptor required for the ERK1/2 activation that 
downregulates PGC-1α following IR AKI we pretreated with erlotinib prior to inducing 
IR AKI. We observed attenuation in the increase of phosphorylated ERK1/2 at 3 hr 
compared to IR alone (Figure 2.7D-E). Very similar to the results obtained in the 
trametinib experiments (Figure 2.6B-C), we observed attenuation of PGC-1α and NRF1 
mRNA compared to the IR group, as well as an increase in PGC-1α protein (Figure 
2.7F-G). The erlotinib group also prevented the 5-fold increase in serum creatinine seen 
in the IR group (Figure 2.7H). These data reveal that EGFR actively regulates ERK1/2 
phosphorylation in the kidney, and as a consequence, EGFR regulates renal PGC-1α 
mRNA at a physiological and pathophysiological level. In summary, EGFR is the 
upstream receptor regulator of basal ERK1/2 phosphorylation in the renal cortex that 





Figure 2.7: Erlotinib blocks ERK1/2 phosphorylation in naïve mice and 
following IR, preventing decreases in PGC-1α and NRF1 expression. A, 
representative immunoblot of phosphorylated ERK1/2 after 4 h of treatment with 
erlotinib in mouse kidney cortex. p, phosphorylated; MW, molecular weight. B, 
densitometry analysis of phosphorylated ERK1/2 when compared with total ERK1/2 
following 4 h of erlotinib treatment. C, mRNA expression of PGC-1α and FOXO1 
at 4 h in mouse cortex following erlotinib treatment. D, representative immunoblot 
of phosphorylated ERK1/2 and total ERK1/2, as well as PGC-1α following IR AKI. 
E, densitometry analysis of phosphorylated ERK1/2 when compared with total 
ERK1/2 following 3 h of IR AKI. F, densitometry analysis of PGC-1α protein when 
compared with β-actin following 3 h of IR AKI. G, mRNA expression of PGC-1α 
and NRF1 following 3 h of IR AKI. H, serum creatinine was assessed 3 h after IR 
AKI. Data are represented as mean S.E., n > 4. Different superscripts indicate 




In this study we identified ERK1/2 as an important and rapid regulator of PGC-1α gene 
transcription in RPTC and in mouse kidney under physiological and pathological 
conditions. In RPTC, we showed trametinib inhibits ERK1/2 phosphorylation within 10 
min leading to an increase in PGC-1α mRNA expression which was sufficient to up-
regulate mitochondrial genes involved in MB. In addition, we determined that EGFR 
was the upstream activator of ERK1/2 in both RPTC and renal cortex. Thus, the 
EGFR/ERK1/2/FOXO(3a/1) pathway is an important negative regulator of PGC-1α and 
its downstream targets, including MB genes. 
 
Previous studies revealed that ERK1/2 down regulates mitochondrial function by 
decreasing basal and uncoupled oxygen consumption following TBHP exposure in 
RPTC (7). Furthermore, ATP production was reduced 40% in RPTC due to ERK1/2 
activation by TBHP, and by inhibiting ERK1/2 ATP remained at control levels. In 
contrast, ERK1/2 inhibition was found to decrease ATP production and cause a rapid 
loss of mitochondrial membrane potential in alveolar macrophages (34), but not in 
primary cultures of tracheobronchial epithelial cells or lung fibroblasts. A decrease in 
oxygen consumption through inhibition of complex I in HL-60 cells was found to occur 
by ERK1/2 inhibition (35). Overall, ERK1/2 decreases mitochondrial function by three 
mechanisms: 1) post-translation modifications that decrease electron transport chain 
activity, 2) down regulation of PGC-1α and mitochondrial gene expression, and 3) 
decreased expression of mitochondrial protectants (i.e. SOD2). However, ERK1/2 
appears to regulate mitochondrial functions differently in various cell types and the 
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differences may be based on the level of oxidative phosphorylation that occurs in each 
cell type. RPTC used by Nowak et al. and in our studies derive all their energy from 
oxidative phosphorylation, similar to that found in kidney cortex. 
 
In RPTC, FOXO3a phosphorylation was decreased 30 min post trametinib treatment. 
These results are consistent with previous studies that show ERK1/2 regulates 
phosphorylation of FOXO3a (23,36). Phosphorylation is a key determinant of FOXO3a 
localization and its regulation of PGC-1α (37-39). Yang et al., showed that ERK1/2 
phosphorylation of FOXO3a promotes a FOXO3a degradation pathway mediated by the 
E3 ubiquitin ligase MDM2 (23). We show that ERK1/2 inhibition decreased 
phosphorylated FOXO3a in the nucleus, allowing greater FOXO3a and PGC-1α 
expression physiologically. This FOXO3a dependent increase in PGC-1α was also 
shown during endothelial oxidative stress (19). 
 
It is not clear the pathway ERK1/2 is being regulated by under these basal conditions. 
Using the specific EGFR inhibitor erlotinib, ERK1/2 phosphorylation was blocked and 
PGC-1α mRNA increased. Thus, EGFR appears to be a key regulator of ERK1/2 which 
in turn regulates the basal level of PGC-1α mRNA and its downstream mitochondrial 
genes. Nevertheless, it remains to be determined what is activating the EGFR under 
these conditions. Possible candidates include EGFR ligands, TGFα and HB-EGF, 
and/or transactivation pathways (ADAM17, ANGII, TWEAK/Fn14) (4,40). 
Inhibiting ERK1/2 increased PGC-1α mRNA, as well as TFAM, NRF1, and COX1. 
The increase in COX1 demonstrates that ERK1/2 is not only increasing nuclear-
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encoded gene expression, but also mitochondrial-encoded gene expression. This 
response is similar to findings in melanoma cell lines after treatment with various ERK 
cascade inhibitors in which an increase in PGC-1α gene expression was observed (41). 
Because FOXO3a was not expressed in naïve mouse renal cortex we shifted focus to 
FOXO1. FOXO3a and FOXO1 share similar DNA-binding domains, have overlapping 
gene expressions (42), and are both directly phosphorylated by ERK1/2 (43). 
Phosphorylation of FOXO1 decreased in the nucleus due to ERK1/2 inhibition, which 
resulted in an increase in downstream targets of FOXO1 (e.g. catalase and SOD2) and 
PGC-1α in the kidney cortex. 
 
During IR-induced AKI in mice, ERK1/2 is highly phosphorylated with accompanying 
decreases in PGC-1α and NRF1, as well as a decline in kidney function at 3 hr post IR 
surgery. Inhibiting phosphorylated ERK1/2 pre-surgery attenuated the PGC-1α and 
NRF1 mRNA decreases and prevented an increase in serum creatinine. We have 
previously shown that PGC-1α is rapidly decreased following diverse models of AKI in 
mice and rats and these results implicate ERK1/2 as the mediator behind this 
transcriptional suppression.  
 
In conclusion we determined the role of ERK1/2  in the physiological and pathological 
regulation of renal PGC-1α and MB.  We linked EGFR activation and FOXO3a/1 
inactivation to the downregulation of PGC-1α and MB, through ERK1/2 signaling. 
PGC-1α physiological regulation appears to be structured so that changes can occur 
very rapidly when necessary. Finally, ERK1/2 inhibition may have potential in 
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preventing mitochondrial dysfunction as a therapeutic strategy in organ dysfunction. 
Because mitochondrial injury/recovery and biogenesis can occur throughout different 
tissues of the body due to various injury insults we think this therapeutic potential of 
inhibiting early activation of ERK1/2 to prevent downregulation of MB may be 





In Vitro Studies 
Female New Zealand White rabbits (2 kg) were purchased from Charles River 
(Oakwood, MI/Canada). Renal proximal tubule cells (RPTC) were isolated using the 
iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved 
conditions similar to what is observed in vivo, as described previously (44). The culture 
medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 (without 
glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5 
mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. 
Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 ug/ml), bovine 
insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM) were added to fresh culture 
medium. Confluent RPTC were used for all experiments. RPTC monolayers were 
treated with various compounds or vehicle (DMSO) for time points indicated. 
 
In Vivo Studies 
Trametinib (GSK1120212, (15)) was purchased from Selleckchem Chemicals (Houston, 
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) mice received an injection 
of trametinib (1 mg/kg i.p.) or vehicle control (DMSO). Four hr after injection kidneys 
were collected and flash frozen for further analysis. 
Mice were assigned to 3 groups: 1) Sham, 2) I/R + Vehicle, 3) I/R + Trametinib. 
Vehicle or trametinib were administered i.p 1 hr before surgery. I/R grouped mice were 
subjected to I/R surgery by bilateral renal pedicle clamping for 18 min as described 
previously (32). Briefly, the renal artery and vein were isolated and blood flow was 
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occluded with a vascular clamp for 18min while maintaining a constant body 
temperature of 36~37°C. Sham mice were treated exactly the same as I/R mice without 
the clamping of the renal pedicles.  Mice were euthanized at 3 h after surgery, and blood 
and kidneys (flash frozen in liquid nitrogen) were collected for analysis. 
 
RT-qPCR Analysis of mRNA Expression 
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life 
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used 
according to the manufacturer’s protocol. The generated cDNA was used with the 
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA 
expression of all genes was determined by the 2−ΔΔCt method, and mouse Actin RNA 




Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with 
protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium 
orthovanadate (Sigma-Aldrich).  
Mouse tissue and rabbit primary cells nuclear and cytosolic fraction lysates were 
prepared as previously described with modifications (11). Briefly, a piece of kidney 
cortex was homogenized in sucrose isolation (ISO) buffer (250 mM sucrose, 1 mM 
EGTA, 10 mM HEPES, 1 mg/ml fatty acid-free BSA [pH 7.4]) with a dounce tissue 
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grinder. Lysates were centrifuged at 1000 x g for 10 min.  The 1st pellet was re-washed 
two separate times in ISO buffer and resuspended in RIPA. The 1st supernatant was 
centrifuged at 10,000 x g for 5 min for further purification of the cytosol fraction. 
Histone H3 and/or Lamin B1 were used as loading control for nuclear lysate 
immunoblots, and alpha-tubulin was used for loading control of cytosolic lysates.  
Equal protein quantities (20–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved 
by gel electrophoresis, and transferred onto nitrocellulose or PVDF membranes (Bio-
Rad). Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and 
incubated overnight with primary antibody at 4°C with gently agitation. Primary 
antibodies used in these studies included (all from Cell Signaling) phospho-ERK1/2 
(1:1000) [#4370], total ERK1/2 (1:1000) [#4695], AKT (1:1000) [#9272], phospho-
AKT (1:1000) [#4060], phospho-p38 (1:1000) [#4511], p38 MAPK (1:1000) [#8690], 
EGF Receptor (1:1000) [#4267], phospho-EGFR Tyr1173 (1:750) [#4407s], phospho-
EGFR Tyr1068 (1:1000) [#3777s], total FOXO3a (1:1000), phospho Ser294-FOXO3a 
(1:1000) [#5538],  and total FOXO1 (1:1000) [#2880] Danvers, MA. Phospho S329-
FOXO1 (1:1000; Abcam) [ab192201], TFAM (1:1000; Abcam) [ab131607], lamin B1 
(1:1000; Abcam) [ab16048], kidney injury molecule-1 (KIM-1) (1:1000; R&D systems, 
Minneapolis, MN) [AF1817], histone H3 (1:2000) [#9715], PGC-1α (1:1000; Abcam) 
[ab54481], and β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [ sc-47778].  
Membranes were incubated with the appropriate horseradish peroxidase–conjugated 
secondary antibody before visualization using enhanced chemiluminescence (Thermo 
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was 





All data are shown as mean ± S.E.M. When comparing two experimental groups, an 
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical 
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc 
test was performed for comparisons of multiple groups. P < 0.05 was considered 
statistically significant. All statistical tests were performed using GraphPad Prism 
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Extracellular Signal-Regulated Kinase 1/2 Regulates Mouse Kidney Injury 







The upregulation of kidney injury molecule-1 (KIM-1) has been extensively studied in 
various renal diseases and following acute injury; however, the initial mechanisms 
controlling KIM-1 expression remain limited. In this study, KIM-1 expression was 
examined in mouse renal cell cultures and in two different models of acute kidney 
injury (AKI), ischemia reperfusion (IR)–induced and lipopolysaccharide (LPS)-induced 
sepsis. KIM-1 mRNA increased in both AKI models, and pharmacological inhibition of 
extracellular signal–regulated kinase 1/2 (ERK1/2) signaling attenuated injury-induced 
KIM-1 expression in the renal cortex. Toll-like receptor 4 knockout (TLR4KO) mice 
exhibited reduced ERK1/2 phosphorylation and attenuated KIM-1 mRNA after LPS 
exposure. TLR4KO mice were not protected from IR-induced ERK1/2 phosphorylation 
and upregulation of KIM-1 mRNA. Following renal IR injury, phosphorylation of 
signal transducer and activator of transcription 3 (STAT3) at serine 727 and tyrosine 
705 increased downstream from ERK1/2 activation. Because phosphorylated STAT3 is 
a transcriptional upregulator of KIM-1 and inhibition of ERK1/2 attenuated increases in 
STAT3 phosphorylation, we suggest an ERK1/2-STAT3-KIM-1 pathway following 
renal injury. Finally, ERK1/2 inhibition in naive mice decreased KIM-1 mRNA and 
nuclear STAT3 phosphorylation in the cortex, indicating homeostatic regulation of 
KIM-1. These findings reveal renal ERK1/2 as an important initial regulator of KIM-1 






KIM-1 is a type I transmembrane glycoprotein that is rapidly upregulated at the gene 
and protein level following various types of injury to the kidney [1-3]. For example, 
KIM-1 is increased in IR, cisplatin, sepsis, folic acid, aristolochic acid and gentamicin-
induced injuries, as well as occurring in disease states, such as renal cell carcinoma, 
polycystic kidney disease, hyperoxaluria, and hypertension [4-7]. 
The ectodomain, which contains an Ig-like domain and a glycosylated mucin domain, is 
cleaved by the metalloproteinase ADAM17 at the cellular membrane [3, 8, 9]. 
Membrane bound KIM-1 and cleaved KIM-1 increase with worsening renal injury [10]. 
KIM-1 is located on the apical surface of renal proximal tubule epithelial cells and 
recognizes phosphatidylserine and oxidized lipoprotein epitopes on the surface of 
apoptotic bodies [11].  
 
The extracellular signal-regulated kinase 1/2 (ERK1/2) is a mitogen-activated protein 
kinase (MAPK) that is phosphorylated rapidly following renal injury [12-14]. We 
previously demonstrated ERK1/2 phosphorylation is elevated 3 hr post IR injury and 1 
hr post LPS induced AKI [15, 16]. Further exploration of the ERK1/2 pathway was 
performed utilizing a specific MEK1/2 inhibitor, trametinib, which inhibits the increase 
in ERK1/2 phosphorylation, since MEK1/2 is directly upstream of ERK1/2 [17, 18]. 
Interestingly, inhibiting LPS induced ERK1/2 phosphorylation prevented KIM-1 
mRNA upregulation at 3 and 18 hr post LPS administration. Smith et al. confirmed 
ERK1/2 inhibition attenuates the upregulation of KIM-1 mRNA following injury 
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utilizing trametinib treatment 6 hr post cecal ligation and puncture (CLP) surgery, a 
model of sepsis [19]. 
 
ERK1/2 and KIM-1 were studied in vitro using a porcine kidney epithelial cell line, 
LLC-PK1, transfected with human KIM-1 [20]. KIM-1 protein promoted cell migration 
and proliferation through activation of the ERK1/2 pathway, and inhibiting ERK1/2 
attenuated these processes. Recently, KIM-1 was shown to modulate macrophages by 
promoting an M1 phenotype and macrophage migration by MAPK pathways, including 
ERK, p38, and JNK [6]. It is clear that ERK1/2 and KIM-1 are activated and 
upregulated shortly after kidney injury, however a direct connection between ERK1/2 
and KIM-1 has received limited study. 
 
Ajay et al. used a combination of bioinformatics, in vitro, and in vivo experiments to 
determine that signal transducer and activator of transcription-3 (STAT3) 
phosphorylation at serine 727 (S727) and tyrosine 705 (Y705) increases KIM-1 
transcription by binding to the KIM-1 specific promoter [21]. Checkpoint kinase 1 
(Chk1) was upregulated following IR injury due to DNA damage which phosphorylated 
STAT3 and subsequently regulated KIM-1 expression [21]. Interestingly, ERK2 was 
the most enriched upstream kinase identified that was associated with the highest 
upregulated transcription factors following IR injury [21-23]. Given this information 
and our previous data demonstrating ERK1/2 is rapidly phosphorylated post IR injury, 




MATERIALS AND METHODS 
In Vitro Studies.  
A transgenic kidney proximal tubule (TK) cell line originally isolated from 
8Tg(SV40E)Bri7 mice and developed by Ernest and Bello-Reuss, was used in all in 
vitro experiments [24, 25]. TK cells were grown in 35-mm tissue culture dishes. The 
culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/F-12 
(without phenol red, or sodium pyruvate) supplemented with 5mM glucose, 10% FBS, 
15 mM HEPES buffer, 2.5 mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium 
bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human 
transferrin (5 ug/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM) 
were added to fresh culture medium. 90-95% confluent TK cells were used for all 
experiments, and FBS was removed from culture media 24 hr before experimentation. 
TK cell monolayers were treated HU (Fisher Scientific- AC151680050), TBHP (Sigma- 
#458139), and H2O2 (Sigma- H1009) or vehicle (DMSO-Sigma) for time points 
indicated. Different TK cell passages used on different days represent the “N” value for 
the in vitro studies.  
 
Naïve and AKI Studies.  
Trametinib (GSK1120212, [18]) was purchased from Selleckchem Chemicals (Houston, 
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) were acquired from Charles 
River Laboratories (Frederick, MD) and received an injection of trametinib (1 mg/kg 
i.p.) or vehicle control (NEOBEE M-5 – Fisher Scientific). Four hr after injection 
kidneys were collected and flash frozen in liquid nitrogen for further analysis. 
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For IR AKI, mice were assigned to 3 groups: 1) Sham, 2) IR + Vehicle, 3) IR + 
Trametinib. Vehicle or trametinib were administered i.p 1 hr before surgery. For 
TLR4KO IR AKI mice were assigned to 4 groups: 1) WT sham, 2) TLR4KO SHAM, 3) 
WT IR, 4) TLR4KO IR. IR grouped mice were subjected to IR surgery by bilateral 
renal pedicle clamping for 18.5 min as described previously [26]. Briefly, the renal 
artery and vein were isolated and blood flow was occluded with a vascular clamp for 
18.5 min while maintaining a constant body temperature of 36~37°C. Sham mice were 
treated exactly the same as IR mice, except without the clamping of the renal pedicles. 
Mice were euthanized at 3 or 24 hr after surgery, and blood and kidneys (flash frozen in 
liquid nitrogen) were collected for analysis. 
For LPS model of sepsis, eight week old male C57BL/6 mice (20–25 g) were given an 
i.p injection of 10 mg/kg LPS derived from Escherichia coli serotype O111:B4 (Sigma-
Aldrich, St. Louis, MO). Control mice received an i.p injection of an equal volume of 
0.9% normal saline. Mice received an injection of GSK1120212 (1 mg/kg i.p.) or 
vehicle control 1 hr before administration of LPS. Mice were euthanized at 18 hr after 
LPS exposure, and kidneys and blood were collected for analysis. Experiments with 
TLR4KO mice were graciously donated by Dr. Kenneth D. Chavin and generated by 
crossing C57BL/10ScN mice with the tlr4LPS-d mutation onto the C57BL/6 
background for at least five generations [16, 27]. All studies were conducted in 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. Animal use was approved by the 





Serum Creatinine Measurement.  
Blood was collected by retro-orbital bleeding puncture and allowed to sit at room 
temperature for 30 minutes. The samples were centrifuged at 10,000 rpm for 10 min to 
separate the serum. Serum creatinine (SCr) was determined using the Creatinine 
Enzymatic Reagent Assay kit (Pointe Scientific, Canton, MI) [c7548-120] based on the 
manufacturer’s directions. All values are expressed as serum creatinine concentration in 
milligrams per deciliter. 
 
RT-qPCR Analysis of mRNA Expression.  
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life 
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used 
according to the manufacturer’s protocol. The generated cDNA was used with the 
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA 
expression of all genes was determined by the 2−ΔΔCt method, and mouse Actin RNA 
and rabbit tubulin RNA were used as reference genes for normalization. KIM-1 primer 
sequences used were Fwd- 5’-GCATCTCTAAGCGTGGTTGC-3’ and Rev- 5’-
TCAGCTCGGGAATGCACAA-3’. 
 
Immunoblot Analysis.  
Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4) with 
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protease inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium 
orthovanadate (Sigma-Aldrich).  
Mouse tissue nuclear and cytosolic fraction lysates were prepared as previously 
described (24096033, 27875304). Briefly, a piece of kidney cortex was homogenized in 
sucrose isolation (ISO) buffer (250 mM sucrose, 1 mM EGTA, 10 mM HEPES, 1 
mg/ml fatty acid-free BSA [pH 7.4]) added fresh, with a dounce tissue grinder. Lysates 
were centrifuged at 1000 x g for 10 min.  The 1st pellet was pushed through 25G needle 
3 times and re-washed three separate times in ISO buffer and resuspended in RIPA. The 
1st supernatant was centrifuged at 10,000 x g for 5 min for further purification of the 
cytosol fraction. Histone H3 and/or Lamin B1 were used as loading control for nuclear 
lysate immunoblots, and alpha-tubulin was used for loading control of cytosolic lysates.  
Equal protein quantities (10–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved 
by gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad). 
Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and 
incubated overnight with primary antibody at 4°C with gently agitation. Primary 
antibodies used in these studies included phospho-ERK1/2 (1:1000) [#4370], total 
ERK1/2 (1:1000) [#4695], phospho-Chk1 (1:1000) [#12302], Chk1 (1:1000) [#2360], 
phospho-STAT3-Tyr705 (1:1000) [#9145], phospho-STAT3-Ser727 (1:1000) [#94994], 
total STAT3 (1:1000) [#9139], Histone H3 (1:2000) [#9715] all from Cell Signaling 
Technology, Danvers, MA. lamin B1 (1:1000; Abcam) [ab16048], phospho-Chk1 
(1:800) [AF2054], kidney injury molecule-1 (KIM-1) (1:1000) [AF1817] from R&D 




Membranes were incubated with the appropriate horseradish peroxidase–conjugated 
secondary antibody before visualization using enhanced chemiluminescence (Thermo 
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was 
determined using the ImageJ software from NIH and Image Studio Lite from LI-COR. 
 
Statistical Analysis.  
All data are shown as mean ± S.E.M. When comparing two experimental groups, an 
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical 
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc 
test was performed for comparisons of multiple groups. P < 0.05 was considered 
statistically significant. All statistical tests were performed using GraphPad Prism 





ERK1/2 Increases KIM-1 mRNA Following Toxicant Exposure in Mouse Renal 
Cells.  
To confirm KIM-1 expression is upregulated following toxicant exposure, cultured 
transgenic mouse kidney proximal tubule (TK) cells were treated with 1 and 10 mM 
hydroxyurea (HU), 0.1 and 1 mM hydrogen peroxide (H2O2), and 350 and 700 µM 
tert-butyl hydroperoxide (TBHP) for 24 hr. HU causes cellular injury by inhibiting 
DNA synthesis and causing DNA damage [28], while H2O2 and TBHP are model 
oxidants that lead to oxidative stress causing protein, lipid, and DNA damage [29]. Each 
toxicant increased KIM-1 mRNA with increasing concentration (Figure 3.1A). KIM-1 
mRNA increased 8-, 3-, and 3-fold in response to 10 mM HU, 1 mM H2O2, and 700 
µM TBHP, respectively (Figure 3.1A). A 1 hr pretreatment with trametinib prevented 
HU, H2O2, and TBHP induced KIM-1 mRNA increases (Figure 3.1B). Interestingly, 
TK cells treated with trametinib alone showed a 54% decrease in KIM-1 mRNA 
compared to vehicle control cells at 24 hr (Figure 3.1B). These data reveal a regulatory 





Figure 3.1: ERK1/2 increases KIM-1 mRNA after toxicant exposure in mouse 
TKPT cells. (A) KIM-1 mRNA expression after 24 hr following exposure to HU, 
H2O2, and TBHP. (B) KIM-1 mRNA measured after 24 hr post toxicant 
administration with or without 1 hour trametinib (GSK) pretreatment. Data are 
represented as mean ± S.E.M., n ≥ 4. Superscripts indicate statistically significant 
differences (P < 0.05);*, significantly different than vehicle control; #, significance 
between same toxicant groups. 
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Early ERK1/2 Activation Mediates STAT3 Phosphorylation Induced KIM-1 
mRNA Upregulation Following IR AKI.  
KIM-1 mRNA increased 4.7-fold 3 hr post IR AKI compared to sham controls (Figure 
3.2A). Trametinib attenuated the KIM-1 mRNA and serum creatinine increases when 
administered 1 hr before IR surgery (Figure 3.2A, 2B). The phosphorylated ERK1/2 to 
total ERK1/2 ratio increased 4.5-fold in the IR groups compared to sham (Figure 3.2C, 
2D). Trametinib also completely inhibited ERK1/2 phosphorylation increases following 
AKI, as observed previously [15, 16].  
Ajay et al. (2014) reported that Chk1 phosphorylation is elevated 3 hr post IR AKI.  In 
contrast, we did not observe any change in phosphorylated Chk1 to total Chk1 ratio 
following IR injury in the presence or absence of trametinib. However, transcription 
factor STAT3 phosphorylation at both activating sites, S727 and Y705, increased 2.5- 
and 3.5-fold after renal IR, respectively (Figure 3.2C, 2E-H) and pretreatment with 
trametinib partially blocked the increase in phosphorylation of STAT3 at S727 and 
Y705 (Figure 3.2G, 2H). These findings suggest that inhibiting ERK1/2 
phosphorylation prevents KIM-1 mRNA upregulation 3 hr post IR AKI by preventing 




Figure 3.2: ERK1/2 mediates 
STAT3 phosphorylation and 
KIM-1 mRNA upregulation 
following 3 hr of IR AKI. (A) 
KIM-1 mRNA expression 
following IR AKI after 3 hr. (B) 
Serum creatinine was assessed 3 
hr after IR AKI. (C) 
Representative immunoblot of 
phosphorylated ERK1/2, total 
ERK1/2, phosphorylated Chk1, 
and total Chk1 following 3 hr of 
IR AKI. (D) Densitometry 
analysis of phosphorylated 
ERK1/2 compared with total 
ERK1/2. (E) Densitometry 
analysis of phosphorylated Chk1 
compared with total Chk1. (F) 
Representative immunoblot of 
phosphorylated STAT3 (S727 and 
Y705) and total STAT3 following 
3 hr of IR AKI. (G and H) 
Densitometry analysis of 
phosphorylated STAT3 (S727 and 
Y705) compared with total 
STAT3. Data are represented as 
mean ± S.E.M., n = 6. Different 
superscripts indicate statistically 
significant differences (P < 0.05). 
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ERK1/2 Inhibition Suppresses KIM-1 mRNA and Protein 24 hr Following IR AKI.  
At 24 hr, KIM-1 mRNA was ~280-fold higher in the IR group compared to sham 
controls (Figure 3.3A). Trametinib partially blocked the increase in KIM-1 mRNA 
(~120-fold higher compared to sham) compared to the IR mice (Figure 3.3A). Serum 
creatinine increased to 1.1 mg/dL in the IR group and pretreatment with trametinib 
attenuated this rise in serum creatinine at 24 hr (Figure 3.3B). STAT3 phosphorylation 
at S727 and Y705 increased following renal IR injury and trametinib pretreatment 
blocked these increases (Figure 3.3D, G-H).  Chk1 phosphorylation decreased in the IR 
group at 24 hr and ERK1/2 inhibition had no influence on Chk1 phosphorylation 
(Figure 3.3D, 3.3F).  Trametinib inhibited ERK1/2 phosphorylation throughout the 24 
hr period after IR surgery (Figure 3.3D, 3.3E). The IR group showed a large 
upregulation in KIM-1 kidney cortex protein that was markedly reduced in the presence 
of trametinib at 24 hr (Figure 3.3C). Because KIM-1 is cleaved from the cell surface, 
KIM-1 protein was measured in the serum to detect any changes in cleavage regulation 
[30]. Serum KIM-1 protein was high in the IR group and was markedly reduced in the 
trametinib group (Figure 3.3C). These findings reveal ERK1/2 remains activated 24 hr 
following IR AKI, which corresponds to increased phosphorylation of STAT3 at S727 
and Y705, and leads to increases in KIM-1 mRNA and protein. This correlates with our 
observations of STAT3 phosphorylation at S727 and Y705 in the trametinib group 
compared to the IR group in our 3 hr study (Figure 3.2F-H). It is clear, however, that 
ERK1/2 and STAT3 are not the only pathway responsible for the later increases in 





Figure 3.3: ERK1/2 mediates KIM-1 mRNA and protein increases and STAT3 
phosphorylation following 24 hr of IR AKI. (A) KIM-1 mRNA expression 
following IR AKI after 24 hr. (B) Serum creatinine was assessed 24 hr after IR AKI. 
(C) Representative immunoblot of renal KIM-1 and serum KIM-1 (n = 2 for serum 
KIM-1) following 24 hr of IR AKI. (D) Representative immunoblot of 
phosphorylated ERK1/2, total ERK1/2, phosphorylated STAT3 (S727 and Y705), 
total STAT3, phosphorylated Chk1, and total Chk1 following IR AKI. (E–H) 
Densitometry analysis of phosphorylated (E) ERK1/2 to total ERK1/2; (F) p-Chk1 to 
total Chk1; (G) p-STAT3 S727 to total STAT3; (H) p-STAT3 Y705 to total STAT3. 
Data are represented as mean ± S.E.M., n ≥ 5, except where indicated. Different 
superscripts indicate statistically significant differences (P < 0.05). 
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ERK1/2 Increases KIM-1 mRNA in Sepsis Induced AKI and Requires TLR4. 
Previously, we demonstrated LPS-induced AKI requires TLR4 mediated ERK1/2 
activation at the initiation of injury to impair kidney function through mitochondrial 
dysfunction and inflammatory cytokines [16]. Similarly, partial attenuation of KIM-1 
mRNA upregulation through ERK1/2 inhibition prior to LPS administration at 18 hrs 
was observed [16]. Here, trametinib treatment prevented KIM-1 protein upregulation 
within the kidney cortex compared to LPS alone at 18 hr (Figure 3.4A). ERK1/2 
phosphorylation was inhibited in the trametinib + LPS group compared to the control 
and LPS group, whereas the LPS group was not different from controls (Figure 3.4A, 
4B). To further illustrate pharmacological ERK1/2 inhibition downregulates KIM-1 
expression, ERK1/2 phosphorylation was studied following LPS in TLR4KO mice, as 
TLR4 is required for LPS-induced kidney dysfunction [16]. TLR4KO mice had reduced 
ERK1/2 phosphorylation compared to WT mice administered LPS (Figure 3.4D, F). 
LPS induced increases in KIM-1 mRNA and KIM-1 protein were attenuated in LPS 
treated TLR4KO mice, connecting ERK1/2 activation and KIM-1 to TLR4 (Figure 
3.4D, E). For confirmation, TLR4 mRNA expression in the TLR4KO mice was 




Figure 3.4: ERK1/2 increases KIM-1 mRNA and protein in LPS-induced AKI 
through TLR4 after 18 hr. (A) Representative immunoblot of KIM-1, 
phosphorylated ERK1/2, and total ERK1/2 following LPS-induced AKI. (B) 
Densitometry analysis of phosphorylated ERK1/2 compared with total ERK1/2. (C) 
TLR4 mRNA measured in WT mice kidney and TLR4KO mice kidney. (D) 
Representative immunoblot of KIM-1, phosphorylated ERK1/2, and total ERK1/2 
following LPS-induced AKI in WT and TLR4KO mice. (E) KIM-1 mRNA 
measured in the kidneys of WT and TLR4KO mice following LPS-induced AKI 
after 18 hr. (F) Densitometry analysis of renal phosphorylated ERK1/2 compared 
with total ERK1/2 in the LPS-treated WT and TLR4KO mice. Data are represented 
as mean ± S.E.M., n ≥ 3. Different superscripts indicate statistically significant 
differences (P < 0.05). 
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TLR4 is Not Required for IR-Induced ERK1/2 Phosphorylation and KIM-1 
mRNA Upregulation.  
To determine if ERK1/2 and KIM-1 are regulated by TLR4 during initiation of injury 
following IR AKI, TLR4KO mice were subjected to IR surgeries and KIM-1 alterations 
were observed at 3 hr. The WT and TLR4KO mice had similar increases in 
phosphorylated ERK1/2 following IR AKI compared to their sham controls (Figure 
3.5A, 5C). Interestingly, KIM-1 mRNA was markedly elevated in the TLR4KO IR mice 
and WT IR mice trended upward (Figure 3.5B). The above findings demonstrate that IR 





Figure 3.5: TLR4 is not required for IR-induced ERK1/2 phosphorylation and 
KIM-1 mRNA upregulation. (A) Representative immunoblot of phosphorylated 
ERK1/2 and total ERK1/2 following IR-induced AKI after 3 hr in WT and TLR4KO 
mice. (B) KIM-1 mRNA measured in the kidneys of WT and TLR4KO mice 
following IR-induced AKI after 3 hr. (C) Densitometry analysis of renal 
phosphorylated ERK1/2 compared with total ERK1/2 in the WT and TLR4KO mice 
following IR-induced AKI. Data are represented as mean ± S.E.M., n ≥ 3. Different 
superscripts indicate statistically significant differences (P < 0.05). 
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ERK1/2 Inhibition Decreases KIM-1 mRNA, and Nuclear and Cytosolic STAT3 
Phosphorylation Under Physiological Conditions.  
To determine if ERK1/2 regulates KIM-1 at a physiological level, naïve mice were 
treated with trametinib or vehicle for 4 hr.  Unexpectedly, trametinib treated mice had 
~55% lower KIM-1 mRNA compared to vehicle control mice (Figure 3.6A). The 
trametinib group had reduced ERK1/2 phosphorylation in the nucleus and cytosol 
(Figure 3.6G, H). Nuclear STAT3 phosphorylation at sites Y705 and S727 were down 
in the trametinib group 55% and 46%, respectively, compared to the vehicle control 
group (Figure 3.6B-D). Phosphorylated Y705 and S727 on STAT3 in the cytosol was 
also reduced in the trametinib group (Figure 3.6E, F).  To confirm that trametinib was 
inhibiting nuclear STAT3 phosphorylation, and subsequently KIM-1 mRNA 
downregulation, cytosol and nuclear fractions were isolated and confirmed for purity 
using α-tubulin and lamin B1 (Figure 3.6H). The purified fractions demonstrated that 
inhibition of physiological ERK1/2 phosphorylation results in a decrease in KIM-1 
mRNA through reducing STAT3 phosphorylation at Y705 and S727 in the kidney. By 
decreasing active STAT3 within the nucleus there is potential for less KIM-1 promoter 







Figure 3.6: ERK1/2 inhibition decreases KIM-1 mRNA and nuclear and 
cytosolic STAT3 phosphorylation under physiologic conditions in naive mice. 
(A) Representative immunoblot of nuclear phosphorylated STAT3 (S727 and Y705) 
and total STAT3 in naive mice after 4-hour treatment with trametinib. (B) KIM-1 
mRNA measured at 4 hr post-treatment with trametinib. (C and D) Densitometry 
analysis of nuclear phosphorylated STAT3 (S727 and Y705) compared with total 
STAT3. (E) Representative immunoblot of cytosol phosphorylated STAT3 (S727 
and Y705) and total STAT3 in naive mice after 4-hour treatment with trametinib. (F) 
Densitometry analysis of cytosol phosphorylated STAT3 (S727 and Y705) 
compared with total STAT3. (G) Densitometry analysis of nuclear and cytosol 
phosphorylated ERK1/2 compared with total ERK1/2. (H) Representative and 
verification renal immunoblot of nuclear and cytosol control proteins with and 
without trametinib treatment. Data are represented as mean ± S.E.M., n ≥ 6. 





Figure 3.7: Visual Abstract. Proposed mechanism of IR, LPS, and ROS-induced 
renal damage that initiates ERK1/2 and STAT3 phosphorylation. STAT3 then binds 
to the KIM-1 promoter and increases KIM-1 mRNA. By preventing ERK1/2 
phosphorylation following renal injury, STAT3 phosphorylation is decreased, 
leading to less phosphorylated STAT3 within the nucleus, and subsequently less 




In this study, ERK1/2 was identified as a regulator of KIM-1 expression. ERK1/2 
inhibition prevented KIM-1 transcription in vitro following toxicant exposure, and 
attenuated increases in KIM-1 mRNA and protein in IR AKI. STAT3 phosphorylation 
at S727 and Y705 decreased as a result of ERK1/2 inhibition, leading to less KIM-1 
expression. In sepsis-induced AKI, TLR4 was required for activation of ERK1/2 and 
KIM-1 upregulation. In contrast, ERK1/2 phosphorylation following IR AKI was not 
dependent on TLR4.  Interestingly, in naïve mice ERK1/2 regulates KIM-1 mRNA by 
physiological STAT3 phosphorylation in the nucleus. We suggest ERK1/2 regulates 
renal KIM-1 expression at a physiological level and initially during pathological renal 
injury by phosphorylation of STAT3.  
The discovery that KIM-1 is the most upregulated gene following AKI led to an 
increase in KIM-1 renal research [2, 3, 31]. Ajay et al. explored the signaling pathway 
that results in upregulation of renal KIM-1 transcription. They reported KIM-1 
transcriptional regulation by Chk1-STAT3 interaction following AKI-induced DNA 
damage. Chk1 was revealed as an upstream kinase of STAT3 and phosphorylation at 
S727 and Y705 on STAT3 was required for KIM-1 upregulation [21]. Phosphorylated 
STAT3 increased following AKI and was found to bind to the KIM-1 promoter, 
therefore increasing KIM-1 mRNA and protein [21]. While our studies support the 
work of Ajay et al., important differences were observed. (1) Chk1 phosphorylation did 
not increase following IR AKI at 3 and 24 hr. (2) ERK1/2 was responsible for the 
STAT3 phosphorylation after IR. (3) Our IR experimental design utilized mice rather 
than rats for AKI. Chk1 phosphorylation did not increase in the renal cortex in our 
123 
 
experiments, yet, KIM-1 mRNA and renal dysfunction was observed. Nevertheless, 
STAT3 phosphorylation was verified to increase following renal injury, and a reduction 
in phosphorylated STAT3 attenuated KIM-1 mRNA. However, ERK1/2 was 
demonstrated as the key initial regulator of STAT3 phosphorylation following renal 
injury, rather than Chk1.  
We previously published work demonstrating that inhibiting the rapid activation of 
ERK1/2 following renal injury prevents and/or attenuates injury and dysfunction 
through restoration of mitochondrial function, renal microvascular perfusion, and 
attenuation of pro-inflammatory cytokines [15, 16, 19]. Here, ERK1/2 involvement with 
STAT3 after renal injury was observed. STAT3 phosphorylation is activated early in 
tubule cells following injury, although the exact role in kidney dysfunction and 
recovery varies in different AKI models [32, 33]. For example, in HgCl2, IR, and 
aristolochic acid induced AKI, early STAT3 phosphorylation was protective [34, 35]. In 
contrast, inhibition of STAT3 phosphorylation in polycystic kidney disease, unilateral 
ureteral obstruction, and HIV-associated nephropathy has shown beneficial outcomes 
[36-38]. Our findings suggest that prevention of renal IR-induced STAT3 
phosphorylation through ERK1/2 inhibition attenuates serum creatinine and KIM-1 
expression. 
Previous experiments demonstrated activated ERK1/2 phosphorylates STAT3 at S727, 
while at the same time decreasing STAT3 Y705 phosphorylation [39-41]. However, in 
our study both S727 and Y705 phosphorylation increased following IR injury and 
decreased with pretreatment with trametinib, suggesting ERK1/2 is responsible for 
phosphorylating both sites. At 24 hr following IR AKI, a partial reduction of KIM-1 
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mRNA in the trametinib group was observed, along with a complete attenuation of 
serum creatinine elevation compared to the IR group.  KIM-1 protein levels were 
substantially lower in the trametinib treated mice, both in the kidney cortex and in the 
circulatory system, as KIM-1 can be detected in the blood. This occurrence has been 
recognized due to the loss of cell polarity, microvascular permeability dysfunction, 
disruption of cell-cell adhesion junctions, and basement membrane cell detachment [6, 
30].  
ERK1/2 phosphorylation was found to regulate KIM-1 expression in a second AKI 
model. LPS-induced AKI increased ERK1/2 phosphorylation and KIM-1 protein, 
whereas trametinib prevented ERK1/2 activation and attenuated the KIM-1 protein 
increase. Further characterization of the ERK1/2-KIM-1 pathway was demonstrated by 
utilization of TLR4KO mice. TLR4 is required for LPS-induced ERK1/2 
phosphorylation and subsequently, KIM-1 mRNA upregulation [16]. ERK1/2 is rapidly 
phosphorylated following LPS at 1 and 3 hr, however in this study, at 18 hr post-LPS 
phosphorylated ERK1/2 was not different than the control group, most likely stemming 
from a prompt compensatory mechanism. Nonetheless, 18 hr after CLP, which is a 
slower developing sepsis model, ERK1/2 phosphorylation is still highly phosphorylated 
compared to controls [16, 19]. To verify that TLR4 signaling was not regulating KIM-1 
expression directly, the TLR4KO mice underwent IR AKI and were compared to the 
wild type mice. There were no differences in ERK1/2 phosphorylation between the 
TLR4KO IR group and the WT IR group, and the TLR4KO group had increased KIM-1 
mRNA. Thus, TLR4 is required for LPS induced ERK1/2 activation and increase in 
KIM-1 mRNA, yet in IR AKI TLR4 is not required since ERK1/2 is activated via other 
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non-TLR4 upstream pathways. Therefore, we view ERK1/2 phosphorylation as a key 
event controlling KIM-1 regulation, and is activated through different pathways in 
different diseases. 
To determine if ERK1/2 regulated KIM-1 at a physiological level, trametinib was 
administered to naïve mice. Although KIM-1 is expressed at very low levels in healthy 
non-injured kidneys, there is a physiological basal level of detection [3, 42]. In the 
absence of an injury, inhibiting physiological ERK1/2 phosphorylation resulted in the 
downregulation of KIM-1 mRNA. This observation correlates with our in vitro results 
that demonstrated trametinib treatment in mouse TK cells decreased KIM-1 mRNA. 
Phosphorylated Chk1 was not altered in the trametinib treated mice (data not shown). 
ERK1/2 phosphorylation was inhibited in the nuclear and cytosolic fractions of the 
kidney cortex, which decreased STAT3 Y705 and S727 phosphorylation in the nucleus. 
Therefore, less active STAT3 is able to bind to the KIM-1 promoter, corresponding to 
the KIM-1 mRNA reduction observed.    
We have provided evidence that STAT3 phosphorylated at Y705 and S727 are partially 
responsible for renal KIM-1 upregulation, and that ERK1/2 involvement is upstream of 
STAT3. These findings provide further evidence that initial ERK1/2 activation is a key 
regulator of various pathways following renal injury, which may lead to the discovery 
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ERK1/2 Regulates NAD+ Metabolism During Acute Kidney Injury Through 






Prior studies have established the important role of extracellular signal-regulated kinase 
1/2 (ERK1/2) as a mediator of acute kidney injury (AKI). We demonstrated rapid 
ERK1/2 activation induced renal dysfunction following ischemia/reperfusion (IR)-
induced AKI and downregulated the mitochondrial biogenesis (MB) regulator, 
peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) in mice. In this 
study, ERK1/2 regulation of cellular NAD+ and PGC-1α were explored. Inhibition of 
ERK1/2 activation using the MEK1/2 inhibitor, trametinib, attenuated renal cortical 
NAD+ depletion after AKI in mice. The rate-limiting NAD biosynthesis salvage 
enzyme, NAMPT, decreased following AKI, and this decrease was prevented by 
ERK1/2 inhibition. The microRNA miR-34a decreased with the inhibition of ERK1/2, 
leading to increased NAMPT protein. Treating mice with a miR34a mimic prevented 
increases in NAMPT protein in the renal cortex in the presence of ERK1/2 inhibition. In 
addition, ERK1/2 activation increased acetylated PGC-1α, the less active form, whereas 
inhibition of ERK1/2 activation prevented an increase in acetylated PGC-1α after AKI 
through SIRT1 and NAD+ attenuation. These results implicate IR-induced ERK1/2 
activation as an important contributor to the downregulation of both PGC-1α and NAD+ 
pathways that ultimately decrease cellular metabolism and renal function. Inhibition of 
ERK1/2 activation prior to the initiation of IR injury attenuated decreases in PGC-1α 





Extracellular regulated kinases 1/2 (ERK1/2) are protein-serine/threonine kinases that 
are activated through phosphorylation by the upstream mitogen-activated protein kinase 
kinase 1/2 (MEK1/2) [1, 2]. This signaling pathway is initiated by various extracellular 
stimuli and intracellular signaling that ultimately targets several physiological and 
pathological pathways [3, 4]. Many reviews have covered the cellular processes that 
ERK1/2 is known to participate, such as proliferation, differentiation, cell survival, 
migration, death, and metabolism [2, 5-9]. Because ERK1/2 regulates a broad array of 
processes, and many of these processes are seemingly opposite in nature, context is very 
important in ERK1/2 signaling. 
We previously demonstrated rapid ERK1/2 activation following renal ischemia-
reperfusion (IR) injury downregulates mitochondrial biogenesis (MB) by decreasing 
PGC-1α, the master regulator of MB, and the downstream targets of MB expression in 
renal cortical epithelial cells [10]. This is especially relevant as epithelial cells of the 
proximal tubules have a high mitochondrial content to produce ATP that drives various 
transport processes. This is not unique to the epithelial cells of the kidney, as the 
epithelium of the intestine, lung (alveolar type II cell), and the liver (hepatocytes) 
require mitochondria for their energy demands [11-14]. To meet the energy demands, 
renal proximal tubules rely on mitochondrial oxidative phosphorylation exclusively and 
any mitochondrial dysfunction can disrupt the energy balance resulting in cellular 
injury/death and prevent recovery from injury [15, 16].  
PGC-1α is a transcriptional coactivator involved in the regulation of cellular and 
mitochondrial metabolism through a number of pathways that include MB, 
132 
 
mitochondrial dynamics, and mitophagy [17-19]. PGC-1α is enriched in tissues with 
high mitochondrial content and energy demands, such as the heart, skeletal muscle, and 
kidney [20-22]. Specifically, PGC-1α is highly expressed in the renal cortical epithelial 
cells and has been demonstrated to play a vital protective role in multiple diverse renal 
diseases, including sepsis, IR injury, diabetes, and fibrosis [19]. 
Using the potent and specific MEK1/2 inhibitor, trametinib, we blocked ERK1/2 
phosphorylation in the kidney of naive mice and observed increases in PGC-1α and 
downstream targets of PGC-1α, including nuclear-encoded mitochondrial transcription 
factor A (TFAM) and nuclear respiratory factor-1 (NRF1), and the mitochondrial-
encoded electron transport chain protein cytochrome c oxidase I (COX1) [10]. ERK1/2 
activation due to IR injury was inhibited by trametinib pretreatment, and attenuated 
PGC-1α mRNA and protein loss, ultimately preventing a rise in serum creatinine, a 
marker of renal dysfunction. Similarly, ERK1/2 inhibition also prevented the 
downregulation of renal PGC-1α in a lipopolysaccharide (LPS)-induced sepsis model in 
mice and attenuated kidney dysfunction [23].  
Overexpression of PGC-1α in cultures of primary rabbit renal proximal tubule epithelial 
cells (RPTC) promoted mitochondrial and cellular recovery following oxidant injury 
[24]. Similar results were obtained in RPTC using a pharmacological compound, 
formoterol, which acts through the β2-adrenergic receptor to increase PGC-1α 
expression leading to an increase in maximal oxygen consumption rate and MB. In vivo 
PGC-1α upregulation using formoterol increased mitochondrial electron transport chain 
proteins and improved renal recovery following IR injury [25, 26].  
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NAD+ is a vital coenzyme used in cellular energy metabolism, redox signaling, and 
contributes to overall cellular health [27, 28]. NAD+ is often depleted during injury or 
disease, and restoration or prevention of this depletion averts worsening injury and 
often promotes recovery [29]. The kidney is highly susceptible to NAD+ depletion as it 
has the lowest NAD+ half-life at ~30 min, yet is also among the highest NAD+ 
containing organs [30].  
Tran et al. reported a connection between PGC-1α and nicotinamide adenine 
dinucleotide (NAD) metabolism [31, 32]. Utilizing both PGC-1α knockout and 
overexpressing transgenic mice, the group determined that PGC-1α is required for less 
severe AKI, including improved renal recovery and increased survival. Additionally, 
the group found that PGC-1α-mediated AKI protection was largely due to the 
prevention of NAD+ depletion through upregulation of the de novo NAD+ pathway. 
Exogenous nicotinamide (NAM) administered to PGC-1α KO mice improved renal 
function after injury by increasing the NAD+ pool [31].  
The importance of NAD+ in the kidney was also confirmed by Guan et al., by 
preventing NAD+ depletion and renal dysfunction in both cisplatin and IR injury-
induced AKI in 3 and 20 month old mice by administering nicotinamide 
mononucleotide (NMN), a NAD+ precursor [33].  NMN also restored NAD+ and SIRT1 
levels [33]. Age associated AKI microarray data pointed to MAPK signaling as an 
important contributor following cisplatin injury, possibly connecting MAPK signaling 
and NAD. However, less is known about the interactions between ERK1/2 and NAD+ 
metabolism in the proximal tubules and kidney. Considering the important roles of 
ERK1/2, PGC-1α, and NAD+ physiologically and pathologically, and our previous 
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reports of ERK1/2 regulation on renal PGC-1α, we hypothesized early ERK1/2 










MATERIALS AND METHODS 
In Vitro Studies.  
Female New Zealand White rabbits (2 kg) were purchased from Charles River 
(Oakwood, MI/Canada). Renal proximal tubule cells (RPTC) were isolated using the 
iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved 
conditions similar to what is observed in vivo [34]. The culture medium was a 1:1 
mixture of Dulbecco’s modified Eagle’s medium/F-12 (without glucose, phenol red, or 
sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 
uM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 
nM), selenium (5 ng/ml), human transferrin (5 ug/ml), bovine insulin (10 nM), and L-
ascorbic acid-2-phosphate (50 uM) were added to fresh culture medium. Confluent 
RPTC were used for all experiments. RPTC monolayers were treated with various 





Naïve and AKI Studies.  
Trametinib (GSK1120212 [35]) was purchased from Selleckchem Chemicals (Houston, 
TX). Eight-to-nine week old male C57BL/6 mice (20–25 g) were acquired from Charles 
River Laboratories (Frederick, MD) and received an injection of trametinib (1 mg/kg) 
or vehicle control (NEOBEE M-5 – Fisher Scientific) intraperitoneally (ip). Four hr 
after injection, kidneys were collected and flash frozen in liquid nitrogen for further 
analysis. 
For IRI-induced AKI, mice were assigned to 3 groups: 1) Sham, 2) IR + Vehicle, 3) IR 
+ trametinib. Vehicle or trametinib were administered ip 1 hr before surgery. In some 
experiments (Figure 3.5), mice were pretreated 48 and 24 hr before IR surgery with 
vehicle, FK866 (20 mg/kg) (Selleckchem) [S2799], or NMN (500 mg/kg) (Sigma-
Aldrich) [N3501] by ip injection [36]. IRI mice were subjected to ischemia/reperfusion 
surgery by bilateral renal pedicle clamping for 18.5 min as described previously [37]. 
Briefly, the renal artery and vein were isolated and blood flow was occluded with a 
vascular clamp while maintaining a constant body temperature of 36.5~37.5°C. Sham 
mice were treated the same as IRI mice, except the renal pedicles were not clamped. 
Mice were euthanized at 3 or 24 hr after surgery, and blood and kidneys (flash frozen in 
liquid nitrogen) were collected for analysis. 
 
Retro-Orbital Injection of microRNA 34a Mimic.  
Polyplus transfection (Illkirch, France) delivery reagent, in vivo-jetPEI, was used for 
delivering microRNA 34a mimic to the kidney. Preparation of delivery reagent was 
carried out according to manufacturer’s instructions. A 5% glucose solution mixed with 
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in vivo-jetPEI was added to a 5% glucose solution containing mirVana miRNA 34a 
mimic. Combined solutions were vortexed and allowed to incubate at RT for 15-20 min. 
Retro-orbital injection was performed using a solution containing 40 ug of miR34a 
mimic and a N/P ratio of 8. An ip injection of vehicle control (NEOBEE M-5) or 
trametinib (1 mg/kg) was administered 2 hr later. Mice were euthanized 6 hr following 
retro-orbital injection. Mice were assigned 3 groups: 1) jetPEI (retro-orbital) + Vehicle 
(ip), 2) miR34a mimic + Vehicle, 3) miR34a mimic + trametinib. 
 
 
Serum Creatinine Measurement.  
Serum creatinine (SCr) was determined using the Creatinine Enzymatic Reagent Assay 
kit (Pointe Scientific, Canton, MI) [c7548-120] based on the manufacturer’s directions. 
All values are expressed as serum creatinine concentration in milligrams per deciliter. 
 
RT-qPCR Analysis of mRNA and microRNA Expression.  
Total RNA was isolated from renal cortical tissue with TRIzol reagent (Life 
Technologies). The iScript Advanced cDNA Synthesis Kit (Bio-Rad) was used 
according to the manufacturer’s protocol. The generated cDNA was used with the 
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad). The relative mRNA 
expression of all genes was determined by the 2−ΔΔCt method, and mouse actin RNA 
and rabbit tubulin RNA were used as reference genes for normalization (see Table 1 for 
Primer pairs). For microRNA the MystiCq microRNA cDNA synthesis kit was used 
according to the manufacturer’s instructions (Sigma-Aldrich) [MIRRT].  MystiCq 
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SYBR green (Sigma-Aldrich) [MIRRM00] and universal PCR primer (Sigma-Aldrich) 
[MIRUP] were used for RT-qPCR. The relative microRNA expression was determined 
by the 2−ΔΔCt method, and the mouse small nucleolar RNA, SNORD48 was used as a 





Immunoblot Analysis.  
Protein was extracted from renal cortex using RIPA assay buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4). Protease 
inhibitor cocktail (1:100), 1 mM sodium fluoride, and 1 mM sodium orthovanadate 
(Sigma-Aldrich) and nicotinamide and 4-phenylbutyrate were added fresh before each 
extraction. 
Equal protein quantities (10–60 μg) were loaded onto 4–15% SDS-PAGE gels, resolved 
by gel electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad). 
Membranes were blocked in 5% bovine serum albumin or 5% milk in TBST and 
incubated overnight with primary antibody at 4°C with gentle agitation. Primary 
antibodies used in these studies included phospho-ERK1/2 (1:1000) [#4370], total 
ERK1/2 (1:1000) [#4695]. β-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX) [ sc-
47778]. 
Membranes were incubated with the appropriate horseradish peroxidase–conjugated 
secondary antibody before visualization using enhanced chemiluminescence (Thermo 
Scientific) and the GE ImageQuant LAS4000 (GE Life Sciences). Optical density was 
determined using the ImageJ software from NIH and Image Studio Lite from LI-COR. 
 
Immunoprecipitation.  
Following protein extraction, protein quantification was performed using Pierce 660 nm 
Assay (ThermoFisher Scientific) [22660]. Equal amounts of protein from every group 
were utilized according to the instructions from Dynabeads Protein G 
Immunoprecipitation Kit (ThermoFisher Scientific). Immunoprecipitation was 
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performed using acetylated-lysine antibody (1:100; Cell Signaling) [#9441]. PGC-1α 
antibody (1:1000; abcam) [ab54481] was used for immunoblotting pull-down and input. 
Veriblot (1:400; abcam) [ab131366] was used for detection of immunoblotted target 
protein before visualization using enhanced chemiluminescence (Thermo Scientific) 
and the GE ImageQuant LAS4000 (GE Life Sciences). 
 
Respirometry Assay:  
Oxygen consumption rate (OCR) was determined using a Seahorse Bioscience XF-96 
instrument as previously described (20465991). RPTC were plated at 18,000 cells per 
well and grown for 36 hr before a 24 hr treatment. The XF-96 protocol consists of five 
measurements of basal OCR (1 measurement/2.5 min), injection of carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma) [#C2920], and four measurements 
of uncoupled OCR (1 measurement/2.5 min). 
 
NAD+ and NADH measurement.  
Quantification of NAD+ and NADH were carried out using the NAD/NADH Assay Kit 
(abcam) [#ab65348] according to the manufacturer's instructions. NAD+ and NADH 
values were normalized to kidney cortex wet weight. 
 
NAMPT Activity Assay.  
To quantify the enzymatic activity of NAMPT in kidney cortex, protein extracts were 
assayed according to the manufacturer’s instructions using the Cyclex NAMPT 




Statistical Analysis.  
All data are shown as mean ± S.E.M. When comparing two experimental groups, an 
unpaired, two-tailed t test or Mann-Whitney U was used to determine statistical 
differences. A one-way analysis of variance (ANOVA) followed by Tukey’s post hoc 
test was performed for comparisons of multiple groups. P < 0.05 was considered 
statistically significant. All statistical tests were performed using GraphPad Prism 






ERK1/2 Inhibition Prevents IR-Induced Downregulation of PGC-1α and 
Downstream MB Targets, and Attenuates Kidney Dysfunction. 
The effect of ERK1/2 activation and inhibition on PGC-1α signaling in the renal cortex 
24 hr after renal IR injury was examined. We previously demonstrated the potent and 
selective MEK1/2 inhibitor trametinib blocks ERK1/2 activation in this model [10] and 
confirmed ERK1/2 phosphorylation increased in the IR group and was blocked by 
trametinib, without a change in total ERK1/2 (Figure 4.1A). PGC-1α mRNA and 
protein decreased ~70% and ~55%, respectively, 24 hr after IR injury (Figure 4.1 B,C). 
Pretreatment with trametinib 1 hr before IR injury partially prevented this decrease in 
PGC-1α mRNA and protein at 24 hr (Figure 4.1 B,C). MB proteins involved in PGC-
1α signaling and the mitochondrial electron transport chain such as nuclear-encoded 
NDUFS1 and  NDUFB8, and the mitochondrial-encoded COX1 decreased after IR 
injury and were completely attenuated by trametinib pretreatment (Figure 4.1 A,B). 
Specific downstream transcriptional targets of PGC-1α, including TFAM, superoxide 
dismutase 2 (SOD2), and forkhead box protein O1 (FOXO1) mRNA, that were 
previously demonstrated to be regulated by ERK1/2 [10] were reduced ~70% after 24 hr 
and was partially attenuated by trametinib (Figure 4.1 C). In addition, the renal 
dysfunction marker, serum creatinine, increased ~10-fold after IR and trametinib 
completely prevented the increase in serum creatinine, and the loss of renal function in 
response to IR injury (Figure 4.1 D). PGC-1α signaling has been shown to play a 
critical role in MB, and preventing and restoring renal function in settings of AKI [10, 
25, 31, 38]. MB proteins and mRNA were consistently decreased 24 hr after injury and 
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trametinib pretreatment partially or completely prevented the decreases, ultimately, 




  Figure 4.1: ERK1/2 Inhibition Prevents IR-Induced Downregulation of PGC-1α 
and Downstream MB Targets, and Attenuates Kidney Dysfunction. A) 
Representative immunoblot of phosphorylated ERK1/2 and PGC-1α following 24 hr 
of IR AKI. B) Densitometry analysis of PGC-1α, NDYFS1, NDUFB8 and COX1. 
C) PGC-1α mRNA expression following IR AKI after 24 hr. D) Serum creatinine 
was assessed 24 hr after IR AKI. Data are represented as mean ± S.E.M., n ≥ 4. 
Different superscripts indicate statistically significant differences (P < 0.05), where 
‘b’ is different from ‘a’ and ‘c’ is different from ‘a’ and ‘b’. 
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ERK1/2 Inhibition Attenuates PGC-1α Acetylation Increases Following 24 hr AKI.  
Because PGC-1α acetylation status alters its activity, particularly following an acute 
injury [39-42], we used acetylated-lysine immunoprecipitation to look at PGC-1α 
acetylation. In the IR group, PGC-1α was more acetylated, meaning less active, 
compared to the sham group (Figure 4.2 A). However, in the trametinib + IR group 
there was less acetylated PGC-1α compared to the IR group and not different than the 
sham group (Figure 4.2 A). PGC-1α is a major target of deacetylation [43, 44] for the 
NAD-dependent deacetylase, SIRT1. SIRT1 deacetylation of PGC-1α has been 
reported to play a critical role during AKI [39, 40]. After IR injury SIRT1 protein was 
decreased and this decrease was prevented in the trametinib + IR group (Figure 4.2 B). 
SIRT1 mRNA was downregulated at 24 hr after IR injury and was not altered in the 
trametinib + IR group (Figure 4.2 B). These results reveal that trametinib pretreatment 
preserves PGC-1α in a more active state by preventing PGC-1α acetylation following 







Figure 4.2: ERK1/2 Inhibition Attenuates PGC-1α Acetylation Increases 
Following 24 hr AKI. A) Representative immunoblot of PGC-1α following IP of 
acetylated lysine. B) Representative immunoblot of SIRT1, and analysis of SIRT1 
protein and mRNA. Data are represented as mean ± S.E.M., n ≥ 4. Different 
superscripts indicate statistically significant differences (P < 0.05). 
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ERK1/2 Inhibition Attenuated NAD+ Loss After 24 hr IR Injury but Not at 3 hr. 
As SIRT1 enzymatic activity is dependent on the availability of cellular NAD+, we 
examined the effect of ERK1/2 activation and inhibition on NAD+ metabolism in the 
renal cortex following renal IR injury [45]. At 3 and 24 hr after renal IR injury 
trametinib pretreatment blocked ERK1/2 phosphorylation (Figure 4.1 A; Fig 4.3 A). 
NAD+ and NADH did not change at 3 hr following IR injury in any group, however the 
ratio trended up in the trametinib + IR group (Figure 4.3 B-D). At 24 hr, NAD+ and 
NADH decreased ~50% with no change in the NAD+:NADH ratio in response to IR 
injury alone (Figure 4.3 E-G). Pretreatment with trametinib 1 hr before IR injury 
partially prevented the decrease of NAD+ without a change in NADH loss, resulting in a 
marked increase in the NAD+:NADH ratio (Figure 4.3 E-G). These results reveal that 
ERK1/2 plays a role in NAD+ metabolism during IR injury and inhibiting ERK1/2 





  Figure 4.3: ERK1/2 Inhibition Attenuated NAD+ Loss After 24 hr IR Injury 
but Not at 3 hr. A) Representative immunoblot of pERK1/2 and tERK1/2 after IR 
AKI at 3 hr. B, C, E, F) NAD+ and NADH Measurement after IR AKI at 3 and 24 
hr in renal cortex. D, G) Ration of NAD+/NADH analyzed after IR AKI at 3 and 
24 hr. Data are represented as mean ± S.E.M., n ≥ 5. Different superscripts 
indicate statistically significant differences (P < 0.05). 
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ERK1/2 Activation Following IR Decreases NAMPT Protein and Trametinib 
Prevents IR-Induced NAMPT Loss.  
To elucidate the mechanism of ERK1/2-mediated NAD+ and NADH loss in renal IR 
injury, protein and mRNA levels of the enzymes responsible for NAD+ biosynthesis 
were measured (Fig 4.7 -Visual abstract). NAMPT protein was measured 3 and 24 hr 
after IR injury and no change was observed at 3 hr (Figure 4.4 A); however, at 24 hr 
NAMPT protein was decreased 50% compared to sham mice (Figure 4.4 B, C). 
Trametinib pretreatment increased NAMPT protein compared to the IR group at 3 hr 
(Figure 4.4 A), and at 24 hr prevented the NAMPT protein loss observed in the IR 
group (Figure 4.4  B, C).  
Protein levels for the three enzymes responsible for conversion of NMN to NAD+ 
revealed that only NMNAT1 was decreased in the IR group and that trametinib 
prevented this decrease (Figure  4.4 B, C). NMNAT2 and NMNAT3 proteins were not 
changed in the IR group nor trametinib + IR group (Figure 4.4 B, C). The activity of 
NAMPT did not change in the IR and trametinib + IR group compared to sham activity 
(Figure 4.4 E). These results reveal that ERK1/2 inhibition increases NAMPT early 
after IR injury and prevents NAMPT and NMNAT1 protein loss 24 hr after IR injury. 
As both NAMPT and NMNAT1 contribute to NAD synthesis, and NAMPT is the rate-
limiting enzyme in the salvage pathway (Figure 4.7 - Visual abstract) [46], and the 
salvage pathway is responsible for greater than 99% of the total NAD synthesis [30], 
ERK1/2 mediated NAD+ loss is the result of NAMPT and NMNAT1 protein loss. 
To determine if the decrease in NAMPT and NMNAT1 proteins was the result of 
decreased transcription, mRNA of the respective proteins were measured. Both vehicle 
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and trametinib-treated IR groups exhibited ~60% reduction in NAMPT and NMNAT1 
mRNA at 24 hr (Figure 4.4 D). Thus, ERK1/2 inhibition did not restore NAMPT and 
NMNAT1 mRNA but did restore protein (Figure 4.4 C), suggesting that ERK1/2 
regulates these enzymes independent of transcription. Other NAD+ salvage enzymes, 
NMNAT3 and NRK1, and the important NAD de novo enzyme, QPRT, also exhibited 
marked decreases in mRNA levels in the IR and trametinib + IR groups [47] (Figure 4.4 
D). These results demonstrate that following IR injury the synthesis of key NAD+ 
metabolizing enzyme mRNA are substantially decreased. 
The microRNA, miR34a, can directly bind to the 3’-UTR of NAMPT mRNA and 
regulate NAMPT protein expression, and are inversely correlated [48]. Because 
NAMPT protein was increased at 3 hr and attenuated at 24 hr in the trametinib + IR 
group (Figure 4.4 A,B), miR34a was measured. At 3 hr miR34a levels decreased in the 
trametinib + IR group and were not altered in the 3 hr IR group (Figure 4.4 F). At 24 hr 
following IR injury, miR34a levels were still decreased in the trametinib + IR group 
compared to the sham and IR groups (Figure 4.4 G).  These results correlate increased 




  Figure 4.4: ERK1/2 Activation Following IR Decreases NAMPT Protein and 
Trametinib Prevents IR-Induced NAMPT Loss. A) Representative immunoblot 
and densitometry of NAMPT after IR AKI at 3 hr. B) Representative immunoblot 
of NAMPT, NMNAT1,2,3 after IR AKI at 24 hr. C) Densitometry analysis of 
NAMPT. D) mRNA expression measured for NAD biosynthetic pathway 
enzymes. E) Activity of NAMPT. F-G) miR34a expression measured after IR AKI 
at 3 and 24 hr. Data are represented as mean ± S.E.M., n ≥ 5. Different 
superscripts indicate statistically significant differences (P < 0.05). 
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ERK1/2 Physiologically Regulates miR34a. ERK1/2 Inhibition Decreases miR-34a, 
leading to increases in NAMPT Protein. 
To examine if ERK1/2 also regulates miR34a and NAMPT protein at a physiological 
level we administered trametinib to naïve mice. Following a 4 hr trametinib treatment, 
ERK1/2 phosphorylation was completely inhibited in the renal cortex (Figure 4.5A). 
NAMPT protein increased 44% in the trametinib group compared to the control group, 
and NAMPT mRNA did not change (Figure 4.5A, B). Concurrently, miR34a expression 
decreased 40% in the trametinib treated group (Figure 4.5B). Interestingly, NAD+ and 
NADH were not altered in response to the increased NAMPT protein (Figure 4.5C). 
These data reveal that ERK1/2 affects NAMPT and miR34a under physiological 
conditions and does so without changing NAD+ and NADH content in mouse renal 
cortex. 
To investigate whether ERK1/2 inhibition-induced increase in NAMPT protein is 
miR34a dependent, we utilized a miR34a mimic to prevent trametinib-induced decrease 
of miR34a. Naïve mice were treated with a mirVana miR34a mimic mixed with in vivo-
jetPEI via retro-orbital injection to prevent trametinib treatment from decreasing 
miR34a [49]. The miR34a mimic increased miR34a levels in both the 34a mimic group 
and in the 34a mimic + trametinib group at least two-fold compared to vehicle (Figure 
4.5D). Increasing miR34a levels in the cortex was not only able to prevent trametinib-
induced NAMPT protein upregulation but also minimally decreased NAMPT protein in 
both the miR34a mimic group and the 34a + trametinib group (Figure 4.5E, F). In 
summary, ERK1/2 phosphorylation appears to regulate miR34a, and inhibition of 
ERK1/2 phosphorylation decreases miR34a, which leads to an increase in NAMPT 
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protein. This ERK1/2/miR34a/NAMPT pathway is prevented by increasing miR34a 
levels using a miR34a mimic, which prevented the trametinib-induced increase in 






Figure 4.5: ERK1/2 Physiologically Regulates miR34a and ERK1/2 Inhibition 
Decreases miR-34a, leading to increases in NAMPT Protein. A) Representative 
immunoblot of pERK1/2, and NAMPT protein 4 hr after trametinib 
administration. B) Densitometry analysis of NAMPT protein, and mRNA and 
miRNA expression measurements of NAMPT and miR34a at 4 hr after trametinib 
treatment. C) NAD+ and NADH content in renal cortex measured at 4 hr after 
trametinib treatment. D) miR34a expression after 34a mimic treatment in mice. E) 
Representative immunoblot of NAMPT protein after 34a mimic treatment in renal 
cortex. F) Densitometry analysis of NAMPT protein after 34a Mimic treatment. 
Data are represented as mean ± S.E.M., n ≥ 5. Different superscripts indicate 
statistically significant differences (P < 0.05). 
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Trametinib-Induced Prevention of Serum Creatinine Elevation Following IR is 
Dependent on NAMPT Activity. 
Because ERK1/2 inhibition increased NAMPT protein in a miR34a dependent pathway 
we sought to clarify the role that NAMPT protein contributes to trametinib-induced 
prevention of serum creatinine elevation in IR-induced AKI. We utilized the NAMPT 
inhibitor, FK866, [50, 51] and mice were pretreated before IR surgery with either 
vehicle or FK866 20 mg/kg [36]. Mice pretreated with trametinib were protected from 
IR-induced serum creatinine increases compared to the Veh + IR group (Figure 4.6 A). 
Mice pretreated with FK866 and subjected to IR exhibited did not have any effect on 
increased serum creatinine in the Veh + IR group. In contrast, mice pretreated with both 
FK866 and trametinib had the same increase in serum creatinine as the Veh + IR and 
FK866 + IR groups, and reversed the protective effect of trametinib (Figure 4.6 A). 
These results provide evidence that ERK1/2 inhibition by trametinib protects against 
IR-induced serum creatinine elevation after 24 hr by maintaining NAMPT and 







Figure 4.6: Trametinib-Induced Prevention of Serum Creatinine Elevation 
Following IR is Dependent on NAMPT Activity. A) Serum creatinine 
measurements following pretreatment with trametinib, FK866, and a combo of 
FK866 and trametinib after IR AKI at 24 hr. Data are represented as mean ± 






Figure 4.7: Visual Abstract. Proposed mechanism of trametinib-induced 




We have previously studied the role of ERK1/2 in PGC-1α signaling under 
physiological and pathological conditions and determined that early activation of 
ERK1/2 following renal IR injury was responsible for the initial decrease in PGC-1α 
mRNA expression, and correlated with kidney dysfunction [10]. Here, we have 
expanded our studies to understand the connection between ERK1/2 and NAD+ 
regulation under physiological and renal IR conditions, and in context with PGC-1α 
signaling. We determined that inhibition of ERK1/2 activation decreased miR34a, the 
microRNA regulator of both SIRT1 and NAMPT (Figure 4.7). The decrease in miR34a 
led to an increase in NAMPT protein under control conditions and attenuated the loss of 
NAMPT and SIRT1 after renal IR injury. Prevention of NAMPT loss attenuated 
decreases in NAD+ following IR injury, and prevented PGC-1α acetylation through 
activation of SIRT1. Furthermore, this trametinib-induced miR34a/NAMPT regulation 
was prevented by pretreatment with a miR34a mimic, indicating increased NAMPT 
protein expression by ERK1/2 inhibition was dependent on miR34a. 
 
Similar to our miR34a results, Choi SE et al., observed NAMPT protein regulation by 
miR34a in the liver of obese mice [48]. Hepatic NAMPT protein was lower in obese 
mice compared to controls, and was regulated by an increase in miR34a. SIRT1 was 
also shown to correspond with miR34a levels, as miR34a can bind to and repress 
NAMPT and SIRT1 mRNA translation [48, 52, 53]. ERK1/2 regulation of miR34a has 
not been well characterized; however, a few studies demonstrated that ERK1/2 
phosphorylation is reduced as a result of a rise in miR34a expression [54, 55]. In liver 
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cancer, active ERK1/2 was shown to phosphorylate exportin-5, which led to a decrease 
in pre-miRNA export from the nucleus and a global reduction in miRNA [56]. 
However, a regulatory connection between a decrease in phosphorylated ERK1/2 and a 
decrease in miR34a expression, as reported in this study, has not been elucidated. 
 
Because NAMPT protein increased at 4 hr after trametinib administration without any 
change in NAMPT mRNA, we conclude ERK1/2 inhibition rapidly decreases miR34a 
in the renal cortex and subsequently, induces an increase in NAMPT protein. Because 
NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway, and proximal 
tubules have been shown to have a high abundance of NAMPT [46, 57, 58], any 
prevention of the loss of this enzyme has the potential to directly impact the NAD+ 
content and severity of the injury. As both Tran et al. and Guan et al. demonstrated 
within the kidney, NAD+ levels can directly influence AKI susceptibility [31, 33]. 
However, this is not a kidney-specific phenomenon, as NAD+ boosting or pathway 
upregulation has been shown to have positive health outcomes relating to multiple 
organs, including the liver, heart, pancreas, skeletal muscle, brain, and nervous system 
[59-66].  
 
NAD+ and NADH were not altered when NAMPT protein increased at 4 hr possibly 
demonstrating the salvage pathway maintains only a fixed NAD+ level physiologically 
without the addition of NAD precursors. However, during an acute renal injury, we 
found that preventing the loss of NAMPT protein led to an attenuation of the NAD+ 
decline at 24 hr following IR injury. In addition, using the NAMPT inhibitor, FK866, 
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we found trametinib treatment did not prevent an increase in serum creatinine if given 
in combination with FK866.  
 
Trametinib administration prevented ERK1/2 phosphorylation in uninjured and IR 
injured renal cortical tissue. PGC-1α expression decreased following IR injury at 24 hr, 
which trametinib pretreatment attenuated. PGC-1α acetylation increased following IR 
injury in mice, which decreases PGC-1α transcriptional co-activator activity [43, 67]. 
Our group has previously demonstrated the SIRT1 activator SRT1720, in an AKI 
model, increased the deacetylation status of PGC-1α allowing for more effective 
recruitment of various transcription factors that stimulate the expression of downstream 
target genes [39, 43]. Here, we demonstrate the same concept using trametinib, and 
observed an increase in deacetylated PGC-1α in the trametinib mice following IR injury 
and an increase in MB associated proteins, including NDUFS1, NDUFB8, and COX1. 
Furthermore, trametinib pretreatment prevented the rise in serum creatinine at 24 hr 
post IR injury observed in the vehicle-treated group.  
Because trametinib altered the acetylation status of PGC-1α and increased PGC-1α 
downstream targets of MB, SIRT1 and the necessary coenzyme for SIRT1 enzymatic 
activity, NAD+, were further studied. The increase in deacetylated PGC-1α due to 
trametinib administration was discovered to likely stem from the attenuation of the 
decrease in SIRT1 protein and NAD+ content following IR injury. The availability of 
NAD+ is directly linked to the activity of SIRT1, therefore having more SIRT1 and 
NAD+ available in the trametinib group prevented a decrease in SIRT1 activity 




An increase of PGC-1α in a renal tubule inducible PGC-1α transgenic mouse model 
upregulated the enzymes of the de novo NAD biosynthetic pathway [31]. The opposite 
was found as a decrease in PGC-1α suppressed the enzymes of the NAD biosynthetic 
pathway, as observed in both Pgc1α−/− uninjured kidneys and WT IR kidneys [31].  We 
observed similar results in our studies where PGC-1α is downregulated and NAD 
content is decreased after renal IR injury ([10] and present). Better renal functional 
outcomes were observed in the PGC-1α transgenic mice compared to controls, and 
worse outcomes were observed in the Pgc1α−/− mice, linking PGC-1α and NAD to AKI 
severity. Here, a decrease in PGC-1α protein and PGC-1α acetylation, prevented renal 
dysfunction as measured by serum creatinine. 
 
These experimental results have identified three important findings: 1) Confirmation of 
ERK1/2 inhibition before IR AKI attenuates the downregulation of PGC-1α and certain 
MB targets, 2) ERK1/2 inhibition is able to decrease miR34a levels acutely leading to 
SIRT1 and NAMPT increases, 3) NAMPT protein is vital for ERK1/2 inhibition-
induced reduction in IR AKI severity (Figure 1A). In addition, trametinib pretreatment 
prevented ERK1/2 phosphorylation and attenuated kidney dysfunction as measured by 
serum creatinine at 24 hrs following IR AKI. ERK1/2 inhibition attenuated decreases in 
PGC-1α protein, PGC-1α acetylation, and specific downstream MB targets, SIRT1 and 
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Elucidating the EGFR Ligand Responsible for ERK1/2-Mediated MB Signaling 
While ERK1/2-mediated MB was elucidated in the scope of this project, there are 
additional questions that remain unanswered. We used the MEK1/2 inhibitor, 
trametinib, to prevent ERK1/2 activation as a consequence of IR injury. By doing so we 
observed a prevention in the downregulation of PGC-1α and PGC-1α downstream gene 
targets. Not only did trametinib pretreatment prevent the negative regulation of PGC-
1α, it prevented a rise in serum creatinine. In chapter two, we made the observation that 
the EGFR inhibitor, erlotinib, also inhibited ERK1/2 phosphorylation. The inhibition of 
ERK1/2 phosphorylation using erlotinib was not as strong as the treatment with 
trametinib, yet, we observed very similar downstream effects. By blocking ERK1/2 
phosphorylation thru inhibiting the EGFR, we increased PGC-1α and NRF1 mRNA in 
our cultured primary rabbit renal proximal tubule cells (RPTC), again, very similar to 
our observation with trametinib. Erlotinib administration to naïve mice decreased 
ERK1/2 activation and increased PGC-1α mRNA, even at a physiological level.  
 
Interestingly, pretreatment with erlotinib blunted the increase in ERK1/2 
phosphorylation typically seen following IR injury in the renal cortex. We observed a 
prevention of PGC-1α mRNA downregulation, as well as an increase in PGC-1α 
protein. Most importantly, this prevention of negative PGC-1α regulation after IR 
injury, prevented a rise in serum creatinine similar to trametinib. It should be noted the 
prevention of the rise of serum creatinine was not as great in the erlotinib groups 
compared to the trametinib groups, but was significant from vehicle + IR group. These 
findings are in contrast to some studies which has suggested EGFR inhibition or the use 
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of waved-2 mice (mice with reduced EGFR tyrosine kinase activity), actually causes 
worsening kidney damage and dysfunction following injury [1-3]. The observation is 
that EGFR inhibition prevents tubule dedifferentiation and proliferation. Our studies 
were not setup to examine those biological functions, however, a one-time dose of 
erlotinib prior to IR injury leading to AKI, seems to be beneficial in the acute phase. 
With only a single dose, however, the drug would be out of the circulatory system in ~ 
24 hr, possibly preventing any dedifferentiation and proliferation effects observed in 
other studies. This contrast in studies brings up an interesting concept, in that global 
inhibition of EGFR signaling may not be the best tactic for preventing AKI.  
 
Because we observed similar downstream prevention of PGC-1α and PGC-1α related 
genes in both our trametinib and erlotinib groups, yet erlotinib did not block ERK1/2 
phosphorylation to the extent trametinib did, there may be a specific ligand that is 
causing the negative regulation of PGC-1α and related MB targets following IR injury. 
In other words, there may be a specific ligand that binds to EGFR and causes ERK1/2 
phosphorylation that is the driving force to negatively regulate PGC-1α and downstream 
MB targets. Therefore, my first future project experiments would focus on finding the 
EGFR ligand responsible for ERK1/2 activation at the initiation of IR injury.  
 
These projects would potentially help identify a pharmacological target more specific 
for pre-treatment before surgeries known to cause renal dysfunction (ex. cardiac 
surgeries). Inhibiting one specific ligand versus inhibiting MEK1/2 or the EGFR would 
be more specific, possibly have less side effects, and contribute to less organ system 
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alterations in patients with other disease states. Another possible benefit of identifying 
one specific ligand that prevents the same downregulation of PGC-1a as ERK1/2 
inhibition is that the ligand inhibitor may be druggable beyond a one-time pretreatment 
dose.  
 
Studies have shown consistent ERK1/2 inhibition following AKI is detrimental and 
worsens kidney function [4-7]. There are only seven known EGFR ligands [8] : 1) 
epidermal growth factor (EGF), 2) transforming growth factor-alpha (TGFA), 3) 
heparin-binding EGF-like growth factor (HB-EGF), 4) betacellulin (BTC), 5) 
amphiregulin (AREG), 6) epiregulin (EREG), 7) epigen (EPGN). Most EGFR ligands 
are upregulated rapidly following renal insult and activate the EGFR through membrane 
bound or cleaved interactions [3, 9, 10]. EGFR ligands are cleaved by proteases and a 
disintegrin and metalloproteinase (ADAMs) [11, 12]. Some preliminary experiments 
using our RPTC cultures has shown that broadly inhibiting matrix metalloproteinase 
(MMPs) using the compounds, marimistat and TAPI-2, we get partial inhibition of 






Figure 5.1: Broad MMP inhibition, using TAPI-2, decreases ERK1/2 





Figure 5.2: Marimistat decreases ERK1/2 phosphorylation at 4 hr 
after dosing in RPTC culture. 
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Mitochondrial Supercomplexes in Relation to Pharmacological Activation of MB 
Our lab has previously demonstrated that pharmacological activation of MB in our 
RPTC cultures increases PGC-1α and downstream MB targets at a mRNA and protein 
level. A phenotypic marker of our MB pharmacological agents is an increase in oxygen 
consumption after the addition of a proton uncoupling agent (FCCP) as measured by the 
Seahorse XF96 Analyzer [15]. By measuring oxygen consumption rate following 
FCCP, we are mimicking how well the mitochondria can handle an injury or outside 
stressor. The higher the oxygen consumption rate the more new mitochondria generated 
following pharmacological treatment, or the more efficient the current mitochondria are 
due to increased electron transport proteins [15-17].  
 
Recently, the electron transport chain (ETC) assembly has been investigated to observe 
the various complexes of the ETC and how they interact with each other. The ETC 
assembly can be static or dynamic, and these complex interactions following injury are 
altered. The term mitochondrial supercomplexes is used to denote ETC complex I, II, 
III, IV, and cytochrome c assembling together as one complex assembly instead of 
multiple individual complexes [18]. As seen below, ETC complexes can be assembled 
into one supercomplexes [19] (Figure 5.3). Mitochondrial supercomplexes with various 
configurations and stoichiometries occur in mitochondria from different sources [20-
24]. However, alterations in mitochondrial supercomplex formation following treatment 
with pharmacological agents that induce renal MB at a physiological and pathological 




MB and mitochondrial supercomplex assembly enhances many of the same biological 
pathways. Mitochondrial supercomplex formation has been shown to enhance 
mitochondrial efficiency, increase respiratory reserve capacity, increase ATP 
production, lower ROS formation, is altered after ischemic injury, and declines with age 
[25-28].  The above-mentioned phenomena are all similar to observations made with 
increased PGC-1α and MB, along with a decline following injury and with age [29-32]. 
Mitochondrial supercomplex assembly was observed following 24 hr IR injury with a 1 
hr pretreatment with vehicle or trametinib (1mg/kg). Figure 5.4 depicts the gel, PVDF 
membrane, and immunoblot for mitochondrial complexes following a modified blue-
native PAGE (BN-PAGE) experiment. Figure 5.5 shows side-by-side a mitochondrial 
supercomplex BN-PAGE from a review article next our experimental BN-PAGE 
following 24 hr IR. No quantifications were performed, however, two supercomplexes, 
complex V assembled with complex III2 + IV1 and complex III2 + IV2, look to be 
increased in the 24 hr IR group, whereas the trametinib treated animals have those 
supercomplexes levels similar to sham. This increase in supercomplex formation in the 
IR group may be a compensatory mechanism in which the damaged cortex needs to be 
as efficient as possible. The trametinib treated animal are not as injured, as previously 
shown in chapter 2 and chapter 4. Therefore, supercomplex formation may not be 
required at 24 hr following IR injury because the scope of the injury does not dictate the 
increased formation of supercomplexes.  
 
Timing may play a crucial role in mitochondrial supercomplex formation following 
injury. As we have only performed a 24 hr time point, much more work following IR 
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injury would need to done to outline a timing pathway in response to IR injury. Various 
supercomplexes may be favored during different time points after IR injury and 
depending on the severity of the injury [33, 34]. Alterations in these supercomplexes 
following administration of a pharmacological agent that induces MB would be of 
interest to further enhance the identification of a pharmacological agent that has the 



















Figure 5.3: A) Mitochondrial electron transport chain complexes depicted in 








Figure 5.4: A) Tris-glycine gel following BN-PAGE using isolated 
mitochondria from the renal cortex of mouse kidneys. B) PVDF 
membrane following BN-PAGE modified protocol. C) Immunoblot of 
PVDF membrane after incubation with mitochondrial complex 






Figure 5.5: Immunoblot of PVDF membrane after modified BN-PAGE 
and incubation with mitochondrial complex antibodies. Next to our image 
is a representative mitochondrial supercomplex image pulled from an 
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